

Table 2: MIPS Benchmark Results Using DY2016 and PY2018 Logic

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)	1	Claims	Outcome	Y	21.7	22	33.33 - 23.54	23.53 - 18.25	18.24 - 14.30	14.29 - 11.55	11.54 - 8.90	8.89 - 6.26	6.25 - 3.34	<= 3.33	No	No	--	--
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)	1	EHR	Outcome	Y	29.3	49.4	83.10 - 67.96	67.95 - 54.09	54.08 - 43.22	43.21 - 34.12	34.11 - 27.28	27.27 - 21.75	21.74 - 15.74	<= 15.73	No	No	--	--
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)	1	Registry/QCQR	Outcome	Y	27.1	34.8	57.89 - 42.37	42.36 - 31.59	31.58 - 25.78	25.77 - 20.94	20.93 - 16.82	16.81 - 12.78	12.77 - 7.70	<= 7.69	No	No	--	--
Diabetes: Low Density Lipoprotein (LDL) Management	2	EHR	Outcome	Y	18.6	39.7	23.91 - 30.91	30.92 - 36.79	36.80 - 41.92	41.93 - 46.01	46.02 - 50.19	50.20 - 54.96	54.97 - 61.53	>= 61.54	No	No	--	--
Diabetes: Low Density Lipoprotein (LDL) Management	2	Registry/QCQR	Outcome	Y	21.6	22.2	2.25 - 2.85	2.86 - 4.34	4.35 - 17.05	17.06 - 27.50	27.51 - 37.08	37.09 - 44.28	44.29 - 52.98	>= 52.99	No	No	--	--
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	5	EHR	Process	Y	21.5	64.6	43.53 - 53.26	53.27 - 62.85	62.86 - 68.74	68.75 - 72.40	72.41 - 77.91	77.92 - 85.18	85.19 - 91.33	>= 91.34	No	No	--	--
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	5	Registry/QCQR	Process	Y	11.8	87.1	79.25 - 82.92	82.93 - 85.52	85.53 - 88.88	88.89 - 91.66	91.67 - 94.43	94.44 - 96.76	96.77 - 99.99	100.00	No	No	--	--
Coronary Artery Disease (CAD): Antiplatelet Therapy	6	Registry/QCQR	Process	Y	11.7	87.3	81.22 - 84.94	84.95 - 87.49	87.50 - 89.56	89.57 - 91.61	91.62 - 93.34	93.35 - 95.80	95.81 - 99.99	100.00	No	No	--	--
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	7	EHR	Process	Y	23.1	74.8	51.35 - 68.22	68.23 - 78.77	78.78 - 82.64	82.65 - 86.32	86.33 - 90.79	90.80 - 94.25	94.26 - 97.60	>= 97.61	No	No	--	--
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	7	Registry/QCQR	Process	Y	15.2	84.2	72.55 - 79.06	79.07 - 84.43	84.44 - 88.51	88.52 - 91.17	91.18 - 94.28	94.29 - 98.03	98.04 - 99.99	100.00	No	No	--	--
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	8	EHR	Process	Y	19.6	73.2	60.00 - 65.78	65.79 - 70.58	70.59 - 74.99	75.00 - 79.99	80.00 - 85.95	85.96 - 90.47	90.48 - 95.99	>= 96.00	No	No	--	--
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	8	Registry/QCQR	Process	Y	8.5	91.1	83.83 - 87.49	87.50 - 90.62	90.63 - 93.09	93.10 - 95.44	95.45 - 97.13	97.14 - 99.99	--	100.00	No	No	--	--
Anti-Depressant Medication Management	9	EHR	Process	Y	32.1	70.7	54.90 - 69.89	69.90 - 80.35	80.36 - 85.86	85.87 - 88.56	88.57 - 90.71	90.72 - 92.96	92.97 - 96.53	>= 96.54	No	No	--	--
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	12	Claims	Process	Y	11.3	96.5	98.99 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	12	EHR	Process	Y	16.7	88.2	82.75 - 87.40	87.41 - 90.76	90.77 - 93.62	93.63 - 96.16	96.17 - 97.87	97.88 - 98.96	98.97 - 99.99	100.00	No	No	--	--
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	12	Registry/QCQR	Process	Y	12.8	95	94.70 - 98.14	98.15 - 99.16	99.17 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Age-Related Macular Degeneration (AMD): Dilated Macular Examination	14	Claims	Process	Y	11.7	97	99.60 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Age-Related Macular Degeneration (AMD): Dilated Macular Examination	14	Registry/QCQR	Process	Y	28.7	80.9	64.21 - 81.81	81.82 - 90.85	90.86 - 95.69	95.70 - 98.64	98.65 - 99.99	--	--	100.00	Yes	No	--	--
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	18	EHR	Process	Y	21.1	73.5	57.14 - 65.83	65.84 - 72.72	72.73 - 78.21	78.22 - 83.12	83.13 - 88.17	88.18 - 92.30	92.31 - 96.32	>= 96.33	No	No	--	--
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	19	Claims	Process	Y	13.1	96.6	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	19	EHR	Process	Y	25	66.8	46.15 - 56.85	56.86 - 65.13	65.14 - 72.38	72.39 - 78.21	78.22 - 84.27	84.28 - 89.93	89.94 - 95.41	>= 95.42	No	No	--	--
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	19	Registry/QCQR	Process	Y	29.9	76.5	52.00 - 72.40	72.41 - 81.47	81.48 - 90.76	90.77 - 96.54	96.55 - 99.99	--	--	100.00	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	21	Claims	Process	Y	17.4	94.5	99.13 - 99.99	--	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	21	Registry/QCQR	Process	Y	11.5	96.6	98.09 - 99.99	--	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	22	Claims	Process	Y	8.7	98.4	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	22	Registry/QCQR	Process	Y	10.2	97.3	98.59 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	23	Claims	Process	Y	11.7	97.3	--	--	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	23	Registry/QCQR	Process	Y	14.8	94.8	95.49 - 99.72	99.73 - 99.99	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older	24	Claims	Process	Y	24.7	85	78.43 - 90.90	90.91 - 94.28	94.29 - 96.29	96.30 - 97.66	97.67 - 99.99	--	--	100.00	Yes	No	--	--
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older	24	Registry/QCQR	Process	Y	38	50.1	9.29 - 18.57	18.58 - 28.56	28.57 - 36.05	36.06 - 60.92	60.93 - 86.66	86.67 - 99.99	--	100.00	No	No	--	--
Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	32	Claims	Process	Y	8.2	96.6	96.15 - 98.03	98.04 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	32	Registry/QCQR	Process	Y	17.3	90.7	84.78 - 91.06	91.07 - 95.23	95.24 - 97.44	97.45 - 99.19	99.20 - 99.99	--	--	100.00	Yes	No	--	--
Screening for Osteoporosis for Women Aged 65-85 Years of Age	39	Claims	Process	Y	27.1	54.4	29.30 - 38.45	38.46 - 45.60	45.61 - 52.33	52.34 - 60.39	60.40 - 69.94	69.95 - 81.57	81.58 - 95.67	>= 95.68	No	No	--	--
Screening for Osteoporosis for Women Aged 65-85 Years of Age	39	Registry/QCQR	Process	Y	31.6	51.5	13.36 - 29.05	29.06 - 47.01	47.02 - 55.92	55.93 - 65.41	65.42 - 73.07	73.08 - 82.50	82.51 - 92.30	>= 92.31	No	No	--	--
Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	41	Claims	Process	Y	30	64.1	35.19 - 41.26	41.27 - 48.27	48.28 - 58.81	58.82 - 77.26	77.27 - 97.13	97.14 - 99.99	--	100.00	No	No	--	--
Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	41	Registry/QCQR	Process	Y	20.9	68.6	55.71 - 62.15	62.16 - 66.66	66.67 - 69.51	69.52 - 73.57	73.58 - 79.02	79.03 - 84.99	85.00 - 98.94	>= 98.95	No	No	--	--
Coronary Artery Bypass Graft (CABG): Use of Internal Mammmary Artery (IMA) in Patients with Isolated CABG Surgery	43	Registry/QCQR	Process	Y	2.1	99	98.51 - 99.14	99.15 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	44	Registry/QCQR	Process	Y	9.9	95.2	94.44 - 96.11	96.12 - 97.23	97.24 - 98.72	98.73 - 99.99	--	--	--	100.00	Yes	No	--	--
Medication Reconciliation Post-Discharge	46	Claims	Process	Y	15	95	96.15 - 98.50	98.51 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Medication Reconciliation Post-Discharge	46	Registry/QCQR	Process	Y	16	94.2	96.15 - 99.43	99.44 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Care Plan	47	Claims	Process	Y	38.6	67.1	18.63 - 36.26	36.27 - 68.14	68.15 - 93.72	93.73 - 98.73	98.74 - 99.99	--	--	100.00	No	No	--	--
Care Plan	47	Registry/QCQR	Process	Y	31.6	73.2	44.99 - 66.16	66.17 - 77.69	77.70 - 86.58	86.59 - 93.74	93.75 - 97.69	97.70 - 99.59	99.60 - 99.99	100.00	No	No	--	--
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	48	Claims	Process	Y	40.7	68	9.49 - 37.92	37.93 - 81.64	81.65 - 98.04	98.05 - 99.99	--	--	--	100.00	Yes	No	--	--
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	48	Registry/QCQR	Process	Y	31.6	70.2	41.23 - 59.05	59.06 - 71.69	71.70 - 81.47	81.48 - 89.32	89.33 - 95.82	95.83 - 99.31	99.32 - 99.99	100.00	No	No	--	--
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	50	Claims	Process	Y	26.7	87.2	85.00 - 94.73	94.74 - 98.52	98.53 - 99.99	--	--	--	--	100.00	Yes	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	50	Registry/QCQR	Process	Y	19.6	90.5	87.50 - 93.54	93.55 - 97.43	97.44 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	51	Claims	Process	Y	37.4	70.9	21.74 - 52.37	52.38 - 81.81	81.82 - 95.82	95.83 - 99.99	--	--	--	100.00	Yes	No	--	--
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	51	Registry/QCQR	Process	Y	22.5	80.7	69.23 - 77.00	77.01 - 82.97	82.98 - 87.94	87.95 - 93.32	93.33 - 95.69	95.70 - 98.36	98.37 - 99.99	100.00	No	No	--	--
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy	52	Claims	Process	Y	13.1	96.4	99.03 - 99.99	--	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy	52	Registry/QCQR	Process	Y	17.1	91	84.21 - 93.97	93.98 - 96.14	96.15 - 97.81	97.82 - 99.99	--	--	--	100.00	Yes	Yes	Yes	Yes
Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	54	Claims	Process	Y	6.1	97.1	95.71 - 97.16	97.17 - 98.10	98.11 - 98.81	98.82 - 99.99	--	--	--	100.00	Yes	No	--	--
Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	54	Registry/QCQR	Process	Y	11.3	94.5	92.86 - 95.94	95.95 - 97.26	97.27 - 98.31	98.32 - 98.86	98.87 - 99.62	99.63 - 99.99	--	100.00	Yes	No	--	--
Appropriate Treatment for Children with Upper Respiratory Infection (URI)	65	EHR	Process	Y	16.6	85.4	74.00 - 82.42	82.43 - 87.90	87.91 - 91.29	91.30 - 93.99	94.00 - 95.99	96.00 - 98.92	98.93 - 99.99	100.00	No	No	--	--
Appropriate Treatment for Children with Upper Respiratory Infection (URI)	65	Registry/QCQR	Process	Y	17.8	88.7	74.19 - 89.18	89.19 - 93.54	93.55 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Appropriate Testing for Children with Pharyngitis	66	EHR	Process	Y	26.8	65.4	43.33 - 56.18	56.19 - 66.66	66.67 - 74.74	74.75 - 80.51	80.52 - 84.43	84.44 - 87.29	87.30 - 91.88	>= 91.89	No	No	--	--
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	67	Registry/QCQR	Process	Y	7.2	98.1	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	68	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hematology: Multiple Myeloma: Treatment with Bisphosphonates	69	Registry/QCQR	Process	Y	27.5	89.7	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	70	Registry/QCQR	Process	Y	6.1	98	97.14 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Breast Cancer: Hormonal Therapy for Stage IC -IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	71	Claims	Process	Y	1.4	99.7	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Breast Cancer: Hormonal Therapy for Stage IC -IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	71	EHR	Process	Y	20.2	85.5	67.27 - 89.99	90.00 - 93.32	93.33 - 94.34	94.35 - 97.29	97.30 - 97.77	97.78 - 99.99	--	100.00	No	No	--	--
Breast Cancer: Hormonal Therapy for Stage IC -IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	71	Registry/QCQR	Process	Y	14.8	94.2	93.62 - 99.46	99.47 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	72	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	72	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	72	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections	76	Claims	Process	Y	23.4	88.4	85.37 - 95.23	95.24 - 98.04	98.05 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections	76	Registry/QCQR	Process	Y	15.6	93.3	91.85 - 96.14	96.15 - 98.88	98.89 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Acute Otitis Externa (AOE): Topical Therapy	91	Claims	Process	Y	27.5	80.3	61.54 - 72.72	72.73 - 86.35	86.36 - 95.82	95.83 - 98.38	98.39 - 99.99	--	--	100.00	Yes	No	--	--
Acute Otitis Externa (AOE): Topical Therapy	91	Registry/QCQR	Process	Y	22	75.8	59.26 - 69.99	70.00 - 74.99	75.00 - 80.83	80.84 - 86.20	86.21 - 92.30	92.31 - 95.44	95.45 - 99.99	100.00	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	93	Claims	Process	Y	12.6	93.9	88.37 - 95.99	96.00 - 97.49	97.50 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	93	Registry/QCQR	Process	Y	15.3	90.4	82.80 - 90.47	90.48 - 94.43	94.44 - 97.61	97.62 - 99.99	--	--	--	100.00	Yes	No	--	--
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	99	Claims	Process	Y	2.7	99.3	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	99	Registry/QCQR	Process	Y	2.7	99	99.39 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	100	Claims	Process	Y	1.4	99.5	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	100	Registry/QCQR	Process	Y	1.1	99.6	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	102	Registry/QCQR	Process	Y	4.6	98.3	98.92 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer	104	Registry/QCQR	Process	Y	10.4	93.7	84.85 - 94.11	94.12 - 95.87	95.88 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment	107	EHR	Process	Y	35.3	65.5	22.86 - 51.99	52.00 - 74.42	74.43 - 84.92	84.93 - 88.45	88.46 - 92.80	92.81 - 95.50	95.51 - 96.47	>= 96.48	No	No	--	--
Osteoarthritis (OA): Function and Pain Assessment	109	Claims	Process	Y	21.6	90.1	89.34 - 96.87	96.88 - 98.73	98.74 - 99.71	99.72 - 99.99	--	--	--	100.00	Yes	No	--	--
Osteoarthritis (OA): Function and Pain Assessment	109	Registry/QCQR	Process	Y	37.9	65.2	15.38 - 35.32	35.33 - 64.99	65.00 - 84.89	84.90 - 95.18	95.19 - 99.99	--	--	100.00	No	No	--	--
Preventive Care and Screening: Influenza Immunization	110	Claims	Process	Y	32.9	58.7	23.29 - 33.13	33.14 - 46.93	46.94 - 62.62	62.63 - 74.35	74.36 - 86.05	86.06 - 97.34	97.35 - 99.99	100.00	No	No	--	--
Preventive Care and Screening: Influenza Immunization	110	EHR	Process	Y	26.3	39.3	14.55 - 21.83	21.84 - 29.00	29.01 - 35.99	36.00 - 43.53	43.54 - 52.13	52.14 - 63.12	63.13 - 78.42	>= 78.43	No	No	--	--
Preventive Care and Screening: Influenza Immunization	110	Registry/QCQR	Process	Y	28.9	55.3	26.89 - 40.48	40.49 - 49.99	50.00 - 57.06	57.07 - 64.78	64.79 - 73.07	73.08 - 82.70	82.71 - 96.43	>= 96.44	No	No	--	--
Pneumococcal Vaccination Status for Older Adults	111	Claims	Process	Y	26.2	68.3	44.78 - 55.87	55.88 - 65.57	65.58 - 73.27	73.28 - 80.67	80.68 - 87.34	87.35 - 93.84	93.85 - 99.68	>= 99.69	No	No	--	--
Pneumococcal Vaccination Status for Older Adults	111	EHR	Process	Y	28.9	46.3	15.40 - 25.61	25.62 - 37.30	37.31 - 47.48	47.49 - 56.46	56.47 - 65.52	65.53 - 75.08	75.09 - 85.70	>= 85.71	No	No	--	--
Pneumococcal Vaccination Status for Older Adults	111	Registry/QCQR	Process	Y	28.4	58	29.93 - 45.27	45.28 - 55.09	55.10 - 62.58	62.59 - 69.99	70.00 - 76.96	76.97 - 83.99	84.00 - 92.88	>= 92.89	No	No	--	--
Breast Cancer Screening	112	Claims	Process	Y	28.1	59.4	33.68 - 45.35	45.36 - 53.21	53.22 - 60.28	60.29 - 67.83	67.84 - 76.55	76.56 - 89.23	89.24 - 99.99	100.00	No	No	--	--
Breast Cancer Screening	112	EHR	Process	Y	26	46.3	19.19 - 31.97	31.98 - 40.58	40.59 - 48.40	48.41 - 55.73	55.74 - 63.12	63.13 - 70.05	70.06 - 78.94	>= 78.95	No	No	--	--
Breast Cancer Screening	112	Registry/QCQR	Process	Y	26.1	60.7	38.69 - 52.53	52.54 - 60.13	60.14 - 65.18	65.19 - 70.17	70.18 - 76.01	76.02 - 82.72	82.73 - 92.04	>= 92.05	No	No	--	--
Colorectal Cancer Screening	113	Claims	Process	Y	29.2	63.1	32.69 - 43.68	43.69 - 55.15	55.16 - 66.09	66.10 - 77.36	77.37 - 86.63	86.64 - 94.51	94.52 - 99.99	100.00	No	No	--	--
Colorectal Cancer Screening	113	EHR	Process	Y	28.9	44.2	12.61 - 23.91	23.92 - 34.31	34.32 - 44.54	44.55 - 54.09	54.10 - 63.63	63.64 - 73.09	73.10 - 83.14	>= 83.15	No	No	--	--
Colorectal Cancer Screening	113	Registry/QCQR	Process	Y	27.1	61.7	37.55 - 53.00	53.01 - 59.91	59.92 - 66.20	66.21 - 73.07	73.08 - 79.48	79.49 - 86.42	86.43 - 93.81	>= 93.82	No	No	--	--
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis	116	Registry/QCQR	Process	Y	36.4	62.4	23.90 - 30.87	30.88 - 38.77	38.78 - 58.80	58.81 - 99.99	--	--	--	100.00	No	No	--	--
Diabetes: Eye Exam	117	Claims	Process	Y	23	89.2	88.98 - 98.44	98.45 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Diabetes: Eye Exam	117	EHR	Process	Y	27.6	84.9	84.83 - 92.85	92.86 - 95.32	95.33 - 96.96	96.97 - 98.19	98.20 - 99.17	99.18 - 99.82	99.83 - 99.99	100.00	Yes	No	--	--
Diabetes: Eye Exam	117	Registry/QCQR	Process	Y	25.5	86.3	80.91 - 92.85	92.86 - 96.53	96.54 - 98.70	98.71 - 99.99	--	--	--	100.00	Yes	No	--	--
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	118	Registry/QCQR	Process	Y	11.1	81.7	74.37 - 77.03	77.04 - 79.84	79.85 - 82.29	82.30 - 84.90	84.91 - 87.31	87.32 - 89.99	90.00 - 95.44	>= 95.45	No	No	--	--
Diabetes: Medical Attention for Nephropathy	119	EHR	Process	Y	18.2	76	64.29 - 70.20	70.21 - 75.27	75.28 - 79.68	79.69 - 83.49	83.50 - 87.36	87.37 - 91.17	91.18 - 94.99	>= 95.00	No	No	--	--
Diabetes: Medical Attention for Nephropathy	119	Registry/QCQR	Process	Y	15	81.4	72.00 - 76.58	76.59 - 80.84	80.85 - 84.02	84.03 - 86.91	86.92 - 90.09	90.10 - 93.23	93.24 - 97.66	>= 97.67	No	No	--	--
Adult Kidney Disease: Laboratory Testing (Lipid Profile)	121	Registry/QCQR	Process	Y	31.7	51.4	18.47 - 28.94	28.95 - 38.84	38.85 - 52.51	52.52 - 61.89	61.90 - 74.99	75.00 - 85.18	85.19 - 94.60	>= 94.61	No	No	--	--
Adult Kidney Disease: Blood Pressure Management	122	Registry/QCQR	Outcome	Y	19.3	84.7	69.20 - 79.16	79.17 - 90.69	90.70 - 95.08	95.09 - 96.47	96.48 - 97.66	97.67 - 98.73	98.74 - 99.99	100.00	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	126	Registry/QCQR	Process	Y	34.4	58.7	16.47 - 37.63	37.64 - 54.54	54.55 - 66.98	66.99 - 77.26	77.27 - 85.10	85.11 - 94.55	94.56 - 99.99	100.00	No	No	--	--
Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	127	Registry/QCQR	Process	Y	35.5	55	11.75 - 28.11	28.12 - 45.27	45.28 - 61.51	61.52 - 72.15	72.16 - 82.77	82.78 - 94.28	94.29 - 99.99	100.00	No	No	--	--
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow Up Plan	128	Claims	Process	Y	27.7	72.6	43.20 - 48.42	48.43 - 58.92	58.93 - 83.56	83.57 - 96.60	96.61 - 99.53	99.54 - 99.99	--	100.00	No	No	--	--
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow Up Plan	128	EHR	Process	Y	23.5	45	28.22 - 31.92	31.93 - 35.34	35.35 - 38.76	38.77 - 42.88	42.89 - 49.18	49.19 - 64.83	64.84 - 85.93	>= 85.94	No	No	--	--
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow Up Plan	128	Registry/QCQR	Process	Y	24.5	67.3	45.12 - 52.05	52.06 - 59.99	60.00 - 68.74	68.75 - 77.77	77.78 - 86.07	86.08 - 92.85	92.86 - 99.42	>= 99.43	No	No	--	--
Documentation of Current Medications in the Medical Record	130	Claims	Process	Y	14	95.6	97.20 - 99.23	99.24 - 99.79	99.80 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Documentation of Current Medications in the Medical Record	130	EHR	Process	Y	19.1	89.3	86.25 - 91.91	91.92 - 94.85	94.86 - 96.69	96.70 - 97.98	97.99 - 98.87	98.88 - 99.54	99.55 - 99.95	>= 99.96	Yes	No	--	--
Documentation of Current Medications in the Medical Record	130	Registry/QCQR	Process	Y	27.2	84.9	77.08 - 90.22	90.23 - 95.97	95.98 - 98.60	98.61 - 99.69	99.70 - 99.99	--	--	100.00	Yes	No	--	--
Pain Assessment and Follow-Up	131	Claims	Process	Y	25.8	87.2	79.10 - 96.36	96.37 - 99.37	99.38 - 99.91	99.92 - 99.99	--	--	--	100.00	Yes	No	--	--
Pain Assessment and Follow-Up	131	Registry/QCQR	Process	Y	37.4	68.3	20.00 - 49.79	49.80 - 77.66	77.67 - 88.49	88.50 - 95.53	95.54 - 99.33	99.34 - 99.99	--	100.00	No	No	--	--
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	134	Claims	Process	Y	39.6	65.3	17.13 - 29.27	29.28 - 65.00	65.01 - 91.46	91.47 - 99.34	99.35 - 99.99	--	--	100.00	No	No	--	--
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	134	EHR	Process	Y	32.2	28.4	0.51 - 1.29	1.30 - 5.09	5.10 - 12.51	12.52 - 25.60	25.61 - 42.30	42.31 - 64.36	64.37 - 83.73	>= 83.74	No	No	--	--
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	134	Registry/QCQR	Process	Y	33.1	63.4	28.44 - 53.24	53.25 - 62.81	62.82 - 71.15	71.16 - 79.90	79.91 - 88.69	88.70 - 96.42	96.43 - 99.99	100.00	No	No	--	--
Melanoma: Continuity of Care - Recall System	137	Registry/QCQR	Structure	Y	20.7	89.9	87.50 - 93.64	93.65 - 96.96	96.97 - 99.99	--	--	--	--	100.00	No	No	--	--
Melanoma: Coordination of Care	138	Registry/QCQR	Process	Y	30.9	78.5	52.38 - 78.97	78.98 - 88.88	88.89 - 95.54	95.55 - 99.99	--	--	--	100.00	Yes	No	--	--
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	140	Claims	Process	Y	14.1	95.2	97.33 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	140	Registry/QCQR	Process	Y	31.1	72.1	35.90 - 57.88	57.89 - 71.75	71.76 - 86.38	86.39 - 94.22	94.23 - 98.31	98.32 - 99.99	--	100.00	No	No	--	--
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	141	Claims	Process	Y	12.3	97.4	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	141	Registry/QCQR	Process	Y	28.4	82.9	69.40 - 86.96	86.97 - 95.04	95.05 - 97.95	97.96 - 99.64	99.65 - 99.99	--	--	100.00	Yes	No	--	--
Oncology: Medical and Radiation - Pain Intensity Quantified	143	EHR	Process	Y	22	87.6	82.07 - 91.90	91.91 - 96.54	96.55 - 99.07	99.08 - 99.86	99.87 - 99.99	--	--	100.00	Yes	No	--	--
Oncology: Medical and Radiation - Pain Intensity Quantified	143	Registry/QCQR	Process	Y	20.7	88.6	82.03 - 90.76	90.77 - 95.39	95.40 - 97.56	97.57 - 99.09	99.10 - 99.99	--	--	100.00	Yes	No	--	--
Oncology: Medical and Radiation - Plan of Care for Pain	144	Registry/QCQR	Process	Y	18.5	91.7	91.74 - 97.13	97.14 - 98.60	98.61 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy	145	Claims	Process	Y	27.6	72.4	47.89 - 63.88	63.89 - 74.90	74.91 - 82.34	82.35 - 87.99	88.00 - 92.58	92.59 - 96.54	96.55 - 99.99	100.00	No	No	--	--
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy	145	Registry/QCQR	Process	Y	21.7	83.6	71.91 - 81.24	81.25 - 87.09	87.10 - 91.66	91.67 - 95.68	95.69 - 98.67	98.68 - 99.99	--	100.00	No	No	--	--
Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Screening Mammograms	146	Claims	Process	Y	0.8	0.2	0.23 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Screening Mammograms	146	Registry/QCQR	Process	Y	3.6	0.5	0.31 - 0.05	0.04 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	147	Claims	Structure	Y	23.5	82.4	66.67 - 79.16	79.17 - 87.49	87.50 - 93.23	93.24 - 96.54	96.55 - 99.99	--	--	100.00	No	No	--	--
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	147	Registry/QCQR	Structure	Y	16.2	90.3	83.67 - 90.71	90.72 - 95.41	95.42 - 97.82	97.83 - 99.99	--	--	--	100.00	No	No	--	--
Falls: Risk Assessment	154	Claims	Process	Y	19.3	93.1	96.84 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Falls: Risk Assessment	154	Registry/QCQR	Process	Y	30.7	77.4	49.22 - 72.83	72.84 - 84.61	84.62 - 95.23	95.24 - 99.88	99.89 - 99.99	--	--	100.00	Yes	No	--	--
Falls: Plan of Care	155	Claims	Process	Y	32.9	75.7	42.25 - 61.32	61.33 - 87.64	87.65 - 98.89	98.90 - 99.99	--	--	--	100.00	Yes	No	--	--
Falls: Plan of Care	155	Registry/QCQR	Process	Y	32.7	76.5	46.15 - 75.12	75.13 - 89.18	89.19 - 94.16	94.17 - 97.32	97.33 - 99.99	--	--	100.00	No	No	--	--
Oncology: Radiation Dose Limits to Normal Tissues	156	Registry/QCQR	Process	Y	5.8	97.5	95.87 - 98.94	98.95 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	160	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Diabetes: Foot Exam	163	EHR	Process	Y	28.8	38.6	9.38 - 16.32	16.33 - 24.01	24.02 - 31.57	31.58 - 44.65	44.66 - 59.08	59.09 - 69.43	69.44 - 79.71	>= 79.72	No	No	--	--
Diabetes: Foot Exam	163	Registry/QCQR	Process	Y	26.8	68.7	47.85 - 55.21	55.22 - 68.09	68.10 - 72.45	72.46 - 83.44	83.45 - 89.76	89.77 - 94.64	94.65 - 98.10	>= 98.11	No	No	--	--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation	164	Registry/QCQR	Outcome	Y	5.3	7.7	12.39 - 9.87	9.86 - 8.74	8.73 - 6.80	6.79 - 5.35	5.34 - 4.23	4.22 - 3.04	3.03 - 1.35	<= 1.34	No	No	--	--
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	165	Registry/QCQR	Outcome	Y	0.8	0.4	0.54 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Coronary Artery Bypass Graft (CABG): Stroke	166	Registry/QCQR	Outcome	Y	1.9	1.4	2.53 - 1.86	1.85 - 1.36	1.35 - 0.88	0.87 - 0.01	--	--	--	0.00	Yes	No	--	--
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	167	Registry/QCQR	Outcome	Y	2.2	2.1	3.74 - 2.79	2.78 - 2.18	2.17 - 1.68	1.67 - 1.19	1.18 - 0.01	--	--	0.00	Yes	No	--	--
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration	168	Registry/QCQR	Outcome	Y	2.5	2.5	3.85 - 3.29	3.28 - 2.68	2.67 - 2.06	2.05 - 1.50	1.49 - 0.95	0.94 - 0.01	--	0.00	No	No	--	--
Rheumatoid Arthritis (RA): Functional Status Assessment	178	Registry/QCQR	Process	Y	32.2	75.4	48.99 - 68.70	68.71 - 81.07	81.08 - 92.77	92.78 - 96.03	96.04 - 99.59	99.60 - 99.99	--	100.00	No	No	--	--
Elder Maltreatment Screen and Follow-Up Plan	181	Claims	Process	Y	36.2	81.9	82.12 - 99.60	99.61 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Elder Maltreatment Screen and Follow-Up Plan	181	Registry/QCQR	Process	Y	30.6	76.5	51.20 - 75.53	75.54 - 83.75	83.76 - 90.28	90.29 - 95.70	95.71 - 98.97	98.98 - 99.99	--	100.00	No	No	--	--
Functional Outcome Assessment	182	Claims	Process	Y	16.8	96	99.95 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Functional Outcome Assessment	182	Registry/QCQR	Process	Y	24.4	91.3	94.95 - 97.20	97.21 - 99.77	99.78 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Colonoscopy Interval for Patients with a History of Adenomatous Polyps.- Avoidance of Inappropriate Use	185	Claims	Process	Y	6.5	97.7	98.00 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Colonoscopy Interval for Patients with a History of Adenomatous Polyps.- Avoidance of Inappropriate Use	185	Registry/QCQR	Process	Y	14.9	93.2	90.91 - 95.99	96.00 - 97.49	97.50 - 99.64	99.65 - 99.99	--	--	--	100.00	Yes	No	--	--
Stroke and Stroke Rehabilitation: Thrombolytic Therapy	187	Registry/QCQR	Outcome	Y	28.5	69.9	52.63 - 57.47	57.48 - 63.88	63.89 - 71.00	71.01 - 80.55	80.56 - 96.52	96.53 - 99.99	--	100.00	No	No	--	--
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	191	EHR	Outcome	Y	16.2	88.1	83.33 - 88.82	88.83 - 91.81	91.82 - 94.11	94.12 - 95.69	95.70 - 96.88	96.89 - 97.98	97.99 - 99.31	>= 99.32	No	No	--	--
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	191	Registry/QCQR	Outcome	Y	20.4	85.6	75.68 - 84.91	84.92 - 91.10	91.11 - 94.35	94.36 - 96.46	96.47 - 97.79	97.80 - 99.99	--	100.00	No	No	--	--
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	192	EHR	Outcome	Y	1.4	0.3	0.33 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	192	Registry/QCQR	Outcome	Y	0.8	0.4	0.50 - 0.18	0.17 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Radiology: Stenosis Measurement in Carotid Imaging Reports	195	Claims	Process	Y	17.1	90.6	85.94 - 92.58	92.59 - 95.91	95.92 - 97.99	98.00 - 99.46	99.47 - 99.99	--	--	100.00	Yes	No	--	--
Radiology: Stenosis Measurement in Carotid Imaging Reports	195	Registry/QCQR	Process	Y	10.1	95	91.92 - 96.04	96.05 - 98.27	98.28 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet	204	Claims	Process	Y	8.9	89.7	83.87 - 86.90	86.91 - 89.00	89.01 - 90.90	90.91 - 92.65	92.66 - 94.58	94.59 - 97.01	97.02 - 99.99	100.00	No	No	--	--
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet	204	EHR	Process	Y	20.1	67.6	53.33 - 61.75	61.76 - 68.32	68.33 - 73.23	73.24 - 77.10	77.11 - 80.60	80.61 - 83.91	83.92 - 87.92	>= 87.93	No	No	--	--
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet	204	Registry/QCQR	Process	Y	14.5	84.1	76.89 - 81.70	81.71 - 84.61	84.62 - 87.16	87.17 - 89.51	89.52 - 91.87	91.88 - 94.89	94.90 - 99.99	100.00	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis	205	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with Knee Impairments	217	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with Hip Impairments	218	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with Foot or Ankle Impairments	219	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with Lumbar Impairments	220	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with Shoulder Impairments	221	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with Elbow, Wrist or Hand Impairments	222	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Status Change for Patients with General Orthopaedic Impairments	223	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Melanoma: Overutilization of Imaging Studies in Melanoma	224	Registry/QCQR	Process	Y	5.4	99.5	--	--	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Radiology: Reminder System for Screening Mammograms	225	Claims	Structure	Y	21.7	91.6	94.20 - 98.22	98.23 - 99.67	99.68 - 99.99	--	--	--	--	100.00	No	No	--	--
Radiology: Reminder System for Screening Mammograms	225	Registry/QCQR	Structure	Y	10.5	97.4	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	226	Claims	Process	Y	7.9	97.4	96.65 - 98.59	98.60 - 99.61	99.62 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	226	EHR	Process	Y	20.2	82.7	72.72 - 82.40	82.41 - 87.55	87.56 - 90.50	90.51 - 92.74	92.75 - 94.63	94.64 - 96.52	96.53 - 98.51	>= 98.52	No	No	--	--
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	226	Registry/QCQR	Process	Y	15.4	88.8	83.72 - 88.38	88.39 - 91.10	91.11 - 93.34	93.35 - 95.44	95.45 - 97.35	97.36 - 99.00	99.01 - 99.99	100.00	No	No	--	--
Controlling High Blood Pressure	236	Claims	Process	Y	18.1	71.4	58.02 - 63.90	63.91 - 68.36	68.37 - 72.91	72.92 - 76.91	76.92 - 81.65	81.66 - 86.95	86.96 - 94.06	>= 94.07	No	No	--	--
Controlling High Blood Pressure	236	EHR	Process	Y	17.5	61.7	51.10 - 56.51	56.52 - 60.77	60.78 - 64.28	64.29 - 67.46	67.47 - 70.93	70.94 - 74.88	74.89 - 80.42	>= 80.43	No	No	--	--
Controlling High Blood Pressure	236	Registry/QCQR	Process	Y	18.7	68.1	56.36 - 62.91	62.92 - 67.53	67.54 - 70.68	70.69 - 73.78	73.79 - 77.45	77.46 - 82.12	82.13 - 88.58	>= 88.59	No	No	--	--
Use of High-Risk Medications in the Elderly	238	EHR	Process	Y	9.4	6.2	12.02 - 6.84	6.83 - 3.53	3.52 - 1.50	1.49 - 0.49	0.48 - 0.01	--	--	0.00	Yes	No	--	--
Use of High-Risk Medications in the Elderly	238	Registry/QCQR	Process	Y	9.7	6.4	11.54 - 7.33	7.32 - 4.11	4.10 - 1.94	1.93 - 0.77	0.76 - 0.24	0.23 - 0.01	--	0.00	Yes	No	--	--
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	239	EHR	Process	Y	13.9	30.3	21.69 - 26.09	26.10 - 28.86	28.87 - 30.47	30.48 - 31.76	31.77 - 32.65	32.66 - 33.32	33.33 - 40.77	>= 40.78	No	No	--	--
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	239	Registry/QCQR	Process	Y	3.9	31.7	29.13 - 30.88	30.89 - 31.54	31.55 - 32.03	32.04 - 32.28	32.29 - 32.44	32.45 - 32.90	32.91 - 33.32	>= 33.33	No	No	--	--
Childhood Immunization Status	240	EHR	Process	Y	18.4	22	4.35 - 8.84	8.85 - 11.95	11.96 - 16.16	16.17 - 23.80	23.81 - 31.25	31.26 - 38.79	38.80 - 50.87	>= 50.88	No	No	--	--
Cardiac Rehabilitation Patient Referral from an Outpatient Setting	243	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Barrett's Esophagus	249	Claims	Structure	Y	1.4	99.8	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Barrett's Esophagus	249	Registry/QCQR	Structure	Y	2.4	99.5	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Radical Prostatectomy Pathology Reporting	250	Registry/QCQR	Structure	Y	4.7	98.1	97.28 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	251	Claims	Structure	Y	0.3	100	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	251	Registry/QCQR	Structure	Y	3.2	99	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	254	Registry/QCQR	Process	Y	2.2	99.2	99.51 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	255	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	255	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	257	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	258	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative Day #2)	259	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)	260	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	261	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	261	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Image Confirmation of Successful Excision of Image-Localized Breast Lesion	262	Registry/QCQR	Process	Y	0.6	99.9	--	--	--	--	--	--	--	100.00	Yes	Yes	Yes	Yes
Preoperative Diagnosis of Breast Cancer	263	Registry/QCQR	Process	Y	1.4	99.3	98.98 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Sentinel Lymph Node Biopsy for Invasive Breast Cancer	264	Registry/QCQR	Process	Y	8.1	97.7	97.87 - 98.98	98.99 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Biopsy Follow-Up	265	Registry/QCQR	Process	Y	29.7	81.6	66.67 - 85.70	85.71 - 92.58	92.59 - 97.80	97.81 - 99.99	--	--	--	100.00	Yes	No	--	--
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	268	Claims	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	268	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy	270	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment	271	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	274	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	275	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Sleep Apnea: Assessment of Sleep Symptoms	276	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Dementia: Staging of Dementia	280	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Dementia: Cognitive Assessment	281	EHR	Process	Y	30.9	63.6	33.33 - 52.77	52.78 - 59.08	59.09 - 69.41	69.42 - 77.77	77.78 - 86.89	86.90 - 95.23	95.24 - 99.99	100.00	No	No	--	--
Dementia: Functional Status Assessment	282	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease	290	Registry/QCQR	Outcome	Y	17.4	87.1	75.76 - 80.76	80.77 - 94.86	94.87 - 95.44	95.45 - 96.66	96.67 - 99.09	99.10 - 99.99	--	100.00	No	No	--	--
Parkinson's Disease: Querying about Sleep Disturbances	292	Registry/QCQR	Outcome	Y	26.1	80.1	60.53 - 79.99	80.00 - 86.10	86.11 - 90.47	90.48 - 95.79	95.80 - 97.43	97.44 - 99.99	--	100.00	No	No	--	--
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	303	Registry/QCQR	Outcome	Y	35.7	58.8	13.16 - 33.32	33.33 - 51.91	51.92 - 72.96	72.97 - 82.75	82.76 - 88.32	88.33 - 92.51	92.52 - 98.91	>= 98.92	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	304	Registry/QCQR	Outcome	Y	36.7	57.3	7.69 - 29.99	30.00 - 49.99	50.00 - 68.74	68.75 - 80.84	80.85 - 86.26	86.27 - 92.16	92.17 - 99.99	100.00	No	No	--	--
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	305	EHR	Process	Y	5.5	3.6	0.49 - 0.65	0.66 - 0.77	0.78 - 0.89	0.90 - 2.10	2.11 - 2.71	2.72 - 4.06	4.07 - 14.48	>= 14.49	No	No	--	--
Cervical Cancer Screening	309	EHR	Process	Y	25.7	34	8.82 - 14.57	14.58 - 20.88	20.89 - 28.29	28.30 - 37.64	37.65 - 47.75	47.76 - 58.15	58.16 - 71.63	>= 71.64	No	No	--	--
Cervical Cancer Screening	309	Registry/QCQR	Process	Y	20.9	60.9	47.34 - 50.87	50.88 - 56.24	56.25 - 60.89	60.90 - 63.33	63.34 - 72.83	72.84 - 79.56	79.57 - 89.45	>= 89.46	No	No	--	--
Chlamydia Screening for Women	310	EHR	Process	Y	21.1	34.5	13.89 - 19.99	20.00 - 28.12	28.13 - 32.80	32.81 - 38.83	38.84 - 48.14	48.15 - 55.17	55.18 - 63.99	>= 64.00	No	No	--	--
Use of Appropriate Medications for Asthma	311	EHR	Process	Y	29.9	60	26.92 - 40.15	40.16 - 57.13	57.14 - 67.85	67.86 - 77.87	77.88 - 83.86	83.87 - 89.05	89.06 - 92.60	>= 92.61	No	No	--	--
Use of Imaging Studies for Low Back Pain	312	EHR	Process	Y	14.5	93.4	90.91 - 96.96	96.97 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Use of Imaging Studies for Low Back Pain	312	Registry/QCQR	Process	Y	8.4	96.6	96.88 - 99.09	99.10 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	317	Claims	Process	Y	24.9	74	49.53 - 57.74	57.75 - 66.45	66.46 - 78.56	78.57 - 90.52	90.53 - 98.16	98.17 - 99.99	--	100.00	No	No	--	--
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	317	EHR	Process	Y	16	28.3	16.53 - 20.40	20.41 - 23.94	23.95 - 26.93	26.94 - 29.99	30.00 - 33.32	33.33 - 37.61	37.62 - 45.98	>= 45.99	No	No	--	--
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	317	Registry/QCQR	Process	Y	27.4	63.9	35.65 - 51.15	51.16 - 64.21	64.22 - 71.25	71.26 - 76.46	76.47 - 81.40	81.41 - 88.06	88.07 - 97.68	>= 97.69	No	No	--	--
Falls: Screening for Future Fall Risk	318	EHR	Process	Y	36.3	50.3	9.14 - 20.16	20.17 - 33.70	33.71 - 48.36	48.37 - 65.67	65.68 - 81.76	81.77 - 93.39	93.40 - 98.80	>= 98.81	No	No	--	--
Falls: Screening for Future Fall Risk	318	Registry/QCQR	Process	Y	27.6	51.5	26.81 - 30.45	30.46 - 37.24	37.25 - 50.39	50.40 - 58.25	58.26 - 68.16	68.17 - 74.99	75.00 - 95.18	>= 95.19	No	No	--	--
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	320	Claims	Process	Y	15.1	93.3	91.51 - 96.40	96.41 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	320	Registry/QCQR	Process	Y	13.2	91.9	87.30 - 91.48	91.49 - 94.25	94.26 - 96.21	96.22 - 98.68	98.69 - 99.99	--	--	100.00	Yes	No	--	--
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	322	Registry/QCQR	Efficiency	Y	21.1	6.5	3.45 - 0.93	0.92 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	323	Registry/QCQR	Efficiency	Y	22	6.6	0.92 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients	324	Registry/QCQR	Efficiency	Y	26.8	13.2	17.89 - 2.36	2.35 - 0.01	--	--	--	--	--	0.00	No	No	--	--
Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	325	Registry/QCQR	Process	Y	29.5	82.2	66.67 - 82.95	82.96 - 91.52	91.53 - 98.04	98.05 - 99.99	--	--	--	100.00	Yes	No	--	--
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	326	Claims	Process	Y	14	94.2	93.91 - 97.29	97.30 - 99.40	99.41 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	326	Registry/QCQR	Process	Y	15.2	82.1	74.17 - 78.28	78.29 - 81.24	81.25 - 83.91	83.92 - 86.37	86.38 - 89.23	89.24 - 93.22	93.23 - 99.99	100.00	No	No	--	--
Pediatric Kidney Disease: Adequacy of Volume Management	327	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL	328	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis	329	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days	330	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Overuse)	331	Registry/QCQR	Process	Y	38.5	52.5	90.10 - 84.63	84.62 - 80.59	80.58 - 68.67	68.66 - 45.11	45.10 - 9.10	9.09 - 1.23	1.22 - 0.01	0.00	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)	332	Registry/QCQR	Process	Y	30.6	60.5	31.58 - 48.27	48.28 - 54.54	54.55 - 61.08	61.09 - 68.08	68.09 - 83.86	83.87 - 95.99	96.00 - 99.99	100.00	No	No	--	--
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)	333	Registry/QCQR	Outcome	Y	4.1	1.9	3.57 - 1.89	1.88 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)	334	Registry/QCQR	Outcome	Y	3.4	1.6	3.13 - 1.40	1.39 - 0.40	0.39 - 0.01	--	--	--	--	0.00	Yes	No	--	--
Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >= 37 and < 39 Weeks (Overuse)	335	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Maternity Care: Post-Partum Follow-Up and Care Coordination	336	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Tuberculosis (TB) Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier	337	Registry/QCQR	Process	Y	29.8	78.1	54.21 - 79.24	79.25 - 87.23	87.24 - 91.75	91.76 - 95.40	95.41 - 96.74	96.75 - 99.99	--	100.00	No	No	--	--
Pain Brought Under Control Within 48 Hours	342	Registry/QCQR	Outcome	Y	25.1	90.1	93.22 - 99.99	--	--	--	--	--	--	100.00	No	No	--	--
Screening Colonoscopy Adenoma Detection Rate	343	Registry/QCQR	Outcome	Y	22.2	51.1	34.48 - 38.73	38.74 - 43.89	43.90 - 48.56	48.57 - 53.18	53.19 - 59.40	59.41 - 67.64	67.65 - 83.99	>= 84.00	No	No	--	--
Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)	344	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS)	345	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA)	346	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital	347	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate	348	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient-Centered Surgical Risk Assessment and Communication	358	Registry/QCQR	Process	Y	36.9	73.8	31.03 - 67.99	68.00 - 91.05	91.06 - 97.11	97.12 - 99.99	--	--	--	100.00	Yes	No	--	--
Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description	359	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	Yes	Yes	No
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies	360	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes	362	Registry/QCQR	Structure	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Studies Through a Secure, Authorized, Media-Free, Shared Archive	363	Registry/QCQR	Structure	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines	364	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hemoglobin A1c Test for Pediatric Patients	365	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hemoglobin A1c Test for Pediatric Patients	365	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	366	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use	367	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
HIV/AIDS: Medical Visit	368	EHR	Process	Y	21.6	51.1	28.74 - 39.12	39.13 - 46.96	46.97 - 52.34	52.35 - 58.55	58.56 - 64.70	64.71 - 71.17	71.18 - 78.37	>= 78.38	No	No	--	--
HIV/AIDS: Medical Visit	368	Registry/QCQR	Process	Y	18.8	79.8	80.00 - 81.24	81.25 - 82.85	82.86 - 84.46	84.47 - 86.35	86.36 - 87.49	87.50 - 89.99	90.00 - 91.29	>= 91.30	No	No	--	--
Pregnant women that had HBsAg testing	369	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pregnant women that had HBsAg testing	369	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Depression Remission at Twelve Months	370	EHR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Depression Remission at Twelve Months	370	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Depression Utilization of the PHQ-9 Tool	371	EHR	Process	Y	22.9	13.9	1.65 - 2.45	2.46 - 3.32	3.33 - 4.32	4.33 - 5.59	5.60 - 8.32	8.33 - 14.99	15.00 - 48.14	>= 48.15	No	No	--	--
Maternal Depression Screening	372	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hypertension: Improvement in Blood Pressure	373	EHR	Outcome	Y	17.3	33.1	17.07 - 22.21	22.22 - 27.26	27.27 - 32.32	32.33 - 37.88	37.89 - 42.85	42.86 - 48.47	48.48 - 55.99	>= 56.00	No	No	--	--
Closing the Referral Loop: Receipt of Specialist Report	374	EHR	Process	Y	29.6	45.3	14.29 - 24.13	24.14 - 33.57	33.58 - 43.65	43.66 - 54.33	54.34 - 63.78	63.79 - 74.99	75.00 - 88.63	>= 88.64	No	No	--	--
Closing the Referral Loop: Receipt of Specialist Report	374	Registry/QCQR	Process	Y	25	87.8	65.22 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Functional Status Assessment for Total Knee Replacement	375	EHR	Process	Y	28.8	37.2	5.08 - 14.80	14.81 - 25.76	25.77 - 36.51	36.52 - 44.73	44.74 - 51.27	51.28 - 60.55	60.56 - 79.99	>= 80.00	No	No	--	--
Functional Status Assessment for Total Hip Replacement	376	EHR	Process	Y	28.5	43.9	10.34 - 26.08	26.09 - 41.66	41.67 - 47.82	47.83 - 56.50	56.51 - 61.15	61.16 - 64.99	65.00 - 72.72	>= 72.73	No	No	--	--
Functional Status Assessments for Congestive Heart Failure	377	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Children Who Have Dental Decay or Cavities	378	EHR	Outcome	Y	0.9	0.2	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Children Who Have Dental Decay or Cavities	378	Registry/QCQR	Outcome	Y	1.3	1.2	1.96 - 1.34	1.33 - 1.08	1.07 - 0.94	0.93 - 0.49	0.48 - 0.43	0.42 - 0.23	0.22 - 0.19	<= 0.18	Yes	No	--	--
Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists	379	EHR	Process	Y	3	2.7	0.36 - 0.54	0.55 - 0.78	0.79 - 1.11	1.12 - 2.03	2.04 - 4.40	4.41 - 5.09	5.10 - 7.36	>= 7.37	No	No	--	--
ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range	380	EHR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
HIV/AIDS: RNA Control for Patients with HIV	381	EHR	Outcome	Y	33.2	59.1	23.63 - 34.99	35.00 - 44.43	44.44 - 52.62	52.63 - 86.51	86.52 - 91.99	92.00 - 93.32	93.33 - 96.42	>= 96.43	No	No	--	--
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment	382	EHR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adherence to Antipsychotic Medications For Individuals with Schizophrenia	383	Registry/QCQR	Outcome	Y	27	81.2	68.57 - 77.77	77.78 - 88.19	88.20 - 93.99	94.00 - 98.85	98.86 - 99.99	--	--	100.00	No	No	--	--
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery	384	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery	385	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences	386	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users	387	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy)	388	Registry/QCQR	Outcome	Y	0.7	0.2	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Cataract Surgery: Difference Between Planned and Final Refraction	389	Registry/QCQR	Outcome	Y	35.6	61.9	13.89 - 38.23	38.24 - 58.48	58.49 - 74.99	75.00 - 82.97	82.98 - 91.90	91.91 - 96.24	96.25 - 99.99	100.00	No	No	--	--
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options	390	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Follow-Up After Hospitalization for Mental Illness (FUH)	391	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision	393	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Lung Cancer Reporting (Biopsy/Cytology Specimens)	395	Claims	Process	Y	11.6	96.9	96.00 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Lung Cancer Reporting (Biopsy/Cytology Specimens)	395	Registry/QCQR	Process	Y	10.7	95.7	95.83 - 96.66	96.67 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Lung Cancer Reporting (Resection Specimens)	396	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Lung Cancer Reporting (Resection Specimens)	396	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Melanoma Reporting	397	Claims	Process	Y	7.9	96.5	95.00 - 97.05	97.06 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Melanoma Reporting	397	Registry/QCQR	Process	Y	15.6	94.5	97.14 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Optimal Asthma Control	398	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk	400	Registry/QCQR	Process	Y	28.7	22.7	1.62 - 2.21	2.22 - 3.22	3.23 - 11.10	11.11 - 19.60	19.61 - 27.21	27.22 - 35.35	35.36 - 68.74	>= 68.75	No	No	--	--
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis	401	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Tobacco Use and Help with Quitting Among Adolescents	402	Registry/QCQR	Process	Y	24.8	80.3	71.85 - 75.75	75.76 - 85.70	85.71 - 89.99	90.00 - 92.58	92.59 - 95.37	95.38 - 97.55	97.56 - 99.99	100.00	No	No	--	--
Adult Kidney Disease: Referral to Hospice	403	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Anesthesiology Smoking Abstinence	404	Registry/QCQR	Process	Y	27.6	64.2	42.86 - 49.99	50.00 - 61.69	61.70 - 66.66	66.67 - 73.90	73.91 - 82.60	82.61 - 91.70	91.71 - 99.99	100.00	No	No	--	--
Appropriate Follow-up Imaging for Incidental Abdominal Lesions	405	Claims	Process	Y	21.2	18.6	33.33 - 22.04	22.03 - 15.39	15.38 - 11.12	11.11 - 7.51	7.50 - 4.21	4.20 - 1.53	1.52 - 0.01	0.00	No	No	--	--
Appropriate Follow-up Imaging for Incidental Abdominal Lesions	405	Registry/QCQR	Process	Y	21.1	15.5	25.00 - 18.19	18.18 - 12.39	12.38 - 8.71	8.70 - 5.09	5.08 - 2.23	2.22 - 0.01	--	0.00	No	No	--	--
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients	406	Claims	Process	Y	24.7	27.2	45.45 - 36.01	36.00 - 30.01	30.00 - 21.63	21.62 - 15.01	15.00 - 8.71	8.70 - 4.18	4.17 - 0.01	0.00	No	No	--	--
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients	406	Registry/QCQR	Process	Y	27	20.1	37.32 - 21.44	21.43 - 15.64	15.63 - 6.57	6.56 - 4.12	4.11 - 1.31	1.30 - 0.01	--	0.00	No	No	--	--
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia	407	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia	407	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Opioid Therapy Follow-up Evaluation	408	Registry/QCQR	Process	Y	23.8	85.9	75.51 - 82.66	82.67 - 92.01	92.02 - 97.78	97.79 - 99.99	--	--	--	100.00	Yes	No	--	--
Clinical Outcome Post Endovascular Stroke Treatment	409	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Psoriasis: Clinical Response to Oral Systemic or Biologic Medications	410	Registry/QCQR	Outcome	Y	31.5	69.7	40.91 - 54.54	54.55 - 70.82	70.83 - 80.30	80.31 - 91.50	91.51 - 95.64	95.65 - 99.99	--	100.00	No	No	--	--
Depression Remission at Six Months	411	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documentation of Signed Opioid Treatment Agreement	412	Registry/QCQR	Process	Y	31.8	78.2	37.14 - 70.37	70.38 - 94.28	94.29 - 99.04	99.05 - 99.99	--	--	--	100.00	Yes	No	--	--
Door to Puncture Time for Endovascular Stroke Treatment	413	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Evaluation or Interview for Risk of Opioid Misuse	414	Registry/QCQR	Process	Y	28.6	85.5	79.89 - 95.34	95.35 - 98.23	98.24 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older	415	Claims	Process	Y	5.5	95.3	90.91 - 93.54	93.55 - 95.44	95.45 - 96.29	96.30 - 99.99	--	--	--	100.00	Yes	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older	415	Registry/QCQR	Process	Y	8.4	92.2	88.52 - 90.35	90.36 - 91.79	91.80 - 94.09	94.10 - 95.41	95.42 - 96.66	96.67 - 97.82	97.83 - 99.99	100.00	No	No	--	--
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years	416	Claims	Efficiency	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years	416	Registry/QCQR	Efficiency	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Open Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive	417	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Osteoporosis Management in Women Who Had a Fracture	418	Registry/QCQR	Process	Y	38.1	29.4	4.29 - 4.99	5.00 - 7.16	7.17 - 10.38	10.39 - 15.57	15.58 - 18.17	18.18 - 88.32	88.33 - 99.99	100.00	No	No	--	--
Overuse Of Neuroimaging For Patients With Primary Headache And A Normal Neurological Examination	419	Registry/QCQR	Process	Y	20.7	92.6	98.23 - 99.27	99.28 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Varicose Vein Treatment with Saphenous Ablation: Outcome Survey	420	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal	421	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury	422	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury	422	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy	423	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy	423	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Perioperative Temperature Management	424	Registry/QCQR	Process	Y	13.2	97.2	99.63 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Photodocumentation of Cecal Intubation	425	Claims	Process	Y	1.6	99.1	98.55 - 98.97	98.98 - 99.56	99.57 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Photodocumentation of Cecal Intubation	425	Registry/QCQR	Process	Y	29.5	82.3	63.36 - 78.52	78.53 - 98.58	98.59 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit (PACU)	426	Registry/QCQR	Process	Y	12.4	97.7	99.78 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU)	427	Registry/QCQR	Process	Y	12.3	97.9	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence	428	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy	429	Claims	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy	429	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy	430	Registry/QCQR	Process	Y	14.6	94.8	95.99 - 98.69	98.70 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	431	Registry/QCQR	Process	Y	35.1	63.7	20.00 - 44.13	44.14 - 63.91	63.92 - 77.43	77.44 - 86.26	86.27 - 92.67	92.68 - 97.07	97.08 - 99.99	100.00	No	No	--	--
Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair	432	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair	433	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Proportion of Patients Sustaining a Ureter Injury at the Time of any Pelvic Organ Prolapse Repair	434	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Quality of Life Assessment For Patients With Primary Headache Disorders	435	Claims	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Quality of Life Assessment For Patients With Primary Headache Disorders	435	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques	436	Claims	Process	Y	30	71.8	51.21 - 67.48	67.49 - 76.69	76.70 - 82.88	82.89 - 87.64	87.65 - 92.25	92.26 - 96.58	96.59 - 99.75	>= 99.76	No	No	--	--
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques	436	Registry/QCQR	Process	Y	23.3	81.2	64.68 - 73.79	73.80 - 81.51	81.52 - 89.00	89.01 - 98.20	98.21 - 99.99	--	--	100.00	No	No	--	--
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure	437	Claims	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure	437	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	438	Registry/QCQR	Process	Y	12.3	71.2	61.47 - 65.40	65.41 - 69.31	69.32 - 71.67	71.68 - 74.37	74.38 - 77.21	77.22 - 81.17	81.18 - 87.22	>= 87.23	No	No	--	--
Age Appropriate Screening Colonoscopy	439	Registry/QCQR	Efficiency	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Asthma: Assessment of Asthma Control ?Ambulatory Care Setting	AAAAI2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment	AAAAI5	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documentation of Clinical Response to Allergen Immunotherapy within One Year	AAAAI6	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documented Rationale to Support Long-Term Aeroallergen Immunotherapy Beyond Five Years, as Indicated	AAAAI7	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year	AAAAI8	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s)	AAAAI9	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documentation of the Consent Process for Subcutaneous Allergen Immunotherapy in the Medical Record	AAAAI10	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Asthma Assessment and Classification	AAAAI11	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Lung Function/Spirometry Evaluation	AAAAI12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient Self-Management and Action Plan	AAAAI14	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Asthma Control: Minimal Important Difference Improvement	AAAAI17	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Penicillin Allergy: Appropriate Removal or Confirmation	AAAAI18	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Distal Symmetric Polyneuropathy: Prediabetes screening	AAN1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Distal Symmetric Polyneuropathy: Screening for Unhealthy Alcohol Use	AAN2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Epilepsy: Seizure Frequency and Seizure Intervention	AAN3	Registry/QCQR	Intermediate Out	Y	9.2	94	88.89 - 93.59	93.60 - 96.99	97.00 - 97.45	97.46 - 98.53	98.54 - 99.36	99.37 - 99.99	--	100.00	Yes	No	--	--
Epilepsy: Screening for Psychiatric or Behavioral Health Disorders	AAN4	Registry/QCQR	Process	Y	25.4	70.9	44.16 - 53.64	53.65 - 67.20	67.21 - 76.64	76.65 - 90.44	90.45 - 93.54	93.55 - 95.56	95.57 - 98.12	>= 98.13	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Headache: Medication prescribed for acute migraine attack	AAN5	Registry/QCQR	Process	Y	16.7	50.9	39.50 - 43.47	43.48 - 45.29	45.30 - 49.99	50.00 - 55.81	55.82 - 59.60	59.61 - 64.72	64.73 - 74.09	>= 74.10	No	No	--	--
Headache: Overuse of Barbiturate Containing Medications for Primary Headache Disorders	AAN6	Registry/QCQR	Process	Y	4.5	97	94.59 - 96.47	96.48 - 97.87	97.88 - 99.26	99.27 - 99.73	99.74 - 99.99	--	--	100.00	Yes	No	--	--
Multiple Sclerosis: Exercise and Appropriate Physical Activity Counseling for Patients with MS	AAN8	Registry/QCQR	Process	Y	25.8	34.4	9.62 - 11.82	11.83 - 18.24	18.25 - 29.22	29.23 - 42.85	42.86 - 53.77	53.78 - 59.56	59.57 - 67.29	>= 67.30	No	No	--	--
Intra-operative anesthesia safety	ABG1	Registry/QCQR	Outcome	Y	3.4	99.5	99.85 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Intra-operative Cardiac Arrest Rate	ABG2	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Intra-operative Mortality Rate	ABG3	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
PACU tracheal intubation Rate	ABG4	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Composite Procedural Safety for All Vascular Access Procedures	ABG5	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Rate of Unplanned Use of Difficult Airway Equipment and/or Failed Airway	ABG6	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Immediate Adult Post-Operative Pain Management	ABG7	Registry/QCQR	Outcome	Y	0	100	99.93 - 99.97	99.98 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Use of Checklist or Protocol for Transfer of Care in Phase I recovery From Anesthesia Provider to PACU or ICU	ABG8	Registry/QCQR	Process	Y	0.1	100	--	--	--	--	--	--	--	100.00	Yes	No	--	--
OR Fire	ABG9	Registry/QCQR	Outcome	N	0	0	--	--	--	--	--	--	--	0.00	--	No	--	--
Day of Surgery Case Cancellation Rate	ABG10	Registry/QCQR	Process	Y	0.4	0.1	0.08 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Anaphylaxis During Anesthesia Care in the Operating Room	ABG11	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Anesthesia: Patient Experience Survey	ABG12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Malignant Hyperthermia	ABG13	Registry/QCQR	Outcome	N	0	0	--	--	--	--	--	--	--	0.00	--	No	--	--
Corneal Abrasion	ABG14	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Dental Injury	ABG15	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Planned use of difficult airway equipment	ABG16	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Medication errors during surgery	ABG17	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Pre-operative Attestation of documentation of current medications in the medical record	ABG18	Registry/QCQR	Process	Y	14.4	97.3	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Unplanned hospital admission post-op, including 23 hr stay	ABG19	Registry/QCQR	Outcome	Y	0.1	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Unplanned transfer ASC to hospital	ABG20	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Pre-operative OSA assessment	ABG21	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Intraoperative Airway Fire	ABG22	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Intraoperative patient fall	ABG23	Registry/QCQR	Outcome	N	0	0	--	--	--	--	--	--	--	0.00	--	No	--	--
Time out error- surgical	ABG24	Registry/QCQR	Process	N	0	0	--	--	--	--	--	--	--	0.00	--	No	--	--
Time out error- regional block	ABG25	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Myocardial Ischemia requiring intervention during the operative period	ABG26	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Dysrhythmia requiring intervention during the operative period	ABG27	Registry/QCQR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Hypertension (HTN): Blood Pressure (BP) Management	ACCPIN1	Registry/QCQR	Outcome	Y	8.5	87	83.41 - 85.41	85.42 - 87.13	87.14 - 88.41	88.42 - 89.85	89.86 - 91.36	91.37 - 92.99	93.00 - 94.71	>= 94.72	No	No	--	--
Coronary Artery Disease (CAD): Blood Pressure Control	ACCPIN2	Registry/QCQR	Outcome	Y	8.7	88.9	85.79 - 87.67	87.68 - 89.28	89.29 - 90.62	90.63 - 91.89	91.90 - 93.08	93.09 - 94.55	94.56 - 96.33	>= 96.34	No	No	--	--
HF: Patient Self Care Education	ACCPIN3	Registry/QCQR	Process	Y	21.3	77.5	57.81 - 71.42	71.43 - 78.78	78.79 - 84.84	84.85 - 89.08	89.09 - 92.58	92.59 - 95.70	95.71 - 98.47	>= 98.48	No	No	--	--
AFIB: CHA2DS2?Asc Score Risk Score Documented	ACCPIN4	Registry/QCQR	Process	Y	21.1	78.8	68.49 - 76.73	76.74 - 82.82	82.83 - 86.45	86.46 - 89.33	89.34 - 91.40	91.41 - 94.72	94.73 - 97.57	>= 97.58	No	No	--	--
CAD: Beta-blocker Therapy: Prior MI or LVSD	ACCPIN5	Registry/QCQR	Process	Y	8.4	75.7	69.54 - 71.78	71.79 - 73.70	73.71 - 75.50	75.51 - 78.00	78.01 - 80.23	80.24 - 82.94	82.95 - 86.42	>= 86.43	No	No	--	--
CAD: Cardiac Rehabilitation Patient Referral from an Outpatient Setting	ACCPIN6	Registry/QCQR	Process	Y	19.5	45.6	33.33 - 38.75	38.76 - 42.28	42.29 - 47.72	47.73 - 49.31	49.32 - 53.63	53.64 - 63.99	64.00 - 67.19	>= 67.20	No	No	--	--
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older	ACEP19	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding	ACEP21	Registry/QCQR	Process	Y	20	16.4	19.06 - 16.74	16.73 - 14.34	14.33 - 11.36	11.35 - 8.90	8.89 - 6.39	6.38 - 4.13	4.12 - 1.46	<= 1.45	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism	ACEP22	Registry/QCQR	Process	Y	13.5	49.2	41.67 - 44.51	44.52 - 46.33	46.34 - 49.17	49.18 - 52.33	52.34 - 56.30	56.31 - 61.01	61.02 - 65.24	>= 65.25	No	No	--	--
Anti-coagulation for Acute Pulmonary Embolism Patients	ACEP23	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pregnancy Test for Female Abdominal Pain Patients	ACEP24	Registry/QCQR	Process	Y	15	75.6	72.00 - 74.23	74.24 - 77.21	77.22 - 79.52	79.53 - 80.52	80.53 - 82.12	82.13 - 84.32	84.33 - 87.17	>= 87.18	No	No	--	--
Tobacco Screening and Cessation Intervention for ED patients with Cardiovascular and/or Pulmonary Conditions	ACEP25	Registry/QCQR	Process	Y	16.6	25.9	11.10 - 15.70	15.71 - 19.29	19.30 - 21.81	21.82 - 24.08	24.09 - 33.50	33.51 - 42.43	42.44 - 51.65	>= 51.66	No	No	--	--
Sepsis Management: Septic Shock: Lactate Level Measurement	ACEP26	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Sepsis Management: Septic Shock: Antibiotics Ordered	ACEP27	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Sepsis Management: Septic Shock: Fluid Resuscitation	ACEP28	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Disease Activity Measurement for Patients with Rheumatoid Arthritis (RA)	ACR1	Registry/QCQR	Process	Y	9.6	89.4	77.78 - 84.77	84.78 - 86.91	86.92 - 89.53	89.54 - 96.04	96.05 - 97.39	97.40 - 98.72	98.73 - 99.94	>= 99.95	No	No	--	--
Functional Status Assessment for Patients with Rheumatoid Arthritis (RA)	ACR2	Registry/QCQR	Process	Y	14.4	87.3	71.25 - 81.84	81.85 - 85.57	85.58 - 93.88	93.89 - 97.51	97.52 - 99.00	99.01 - 99.99	--	100.00	No	No	--	--
Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapy for Active Rheumatoid Arthritis (RA)	ACR3	Registry/QCQR	Process	Y	4.9	92.8	88.93 - 90.60	90.61 - 93.12	93.13 - 94.42	94.43 - 95.11	95.12 - 95.72	95.73 - 96.91	96.92 - 97.79	>= 97.80	No	No	--	--
Tuberculosis Test Prior to First Course Biologic Therapy	ACR4	Registry/QCQR	Process	Y	10.2	81.1	71.43 - 74.99	75.00 - 78.56	78.57 - 82.59	82.60 - 86.04	86.05 - 87.49	87.50 - 91.17	91.18 - 93.64	>= 93.65	No	No	--	--
Glucocorticosteroids and Other Secondary Causes	ACR5	Registry/QCQR	Process	Y	10.3	82.8	73.66 - 79.09	79.10 - 81.53	81.54 - 84.74	84.75 - 88.51	88.52 - 89.73	89.74 - 92.40	92.41 - 94.73	>= 94.74	No	No	--	--
Serum Urate Monitoring	ACR6	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Gout: Serum Urate Target	ACR7	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Gout: ULT Therapy	ACR8	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
CT Colonography True Positive Rate	ACRAD1	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
CT Colonography Clinically Significant Extracolonic Findings	ACRAD2	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Screening Mammography Cancer Detection Rate (CDR)	ACRAD3	Registry/QCQR	Outcome	Y	2.1	5.1	3.43 - 3.86	3.87 - 4.43	4.44 - 4.78	4.79 - 5.21	5.22 - 6.16	6.17 - 7.04	7.05 - 7.55	>= 7.56	No	No	--	--
Screening Mammography Invasive Cancer Detection Rate (ICDR)	ACRAD4	Registry/QCQR	Outcome	Y	2	4.4	2.67 - 3.11	3.12 - 3.48	3.49 - 3.86	3.87 - 4.82	4.83 - 5.30	5.31 - 5.97	5.98 - 7.08	>= 7.09	No	No	--	--
Screening Mammography Abnormal Interpretation Rate (Recall Rate)	ACRAD5	Registry/QCQR	Outcome	Y	5.2	9.8	12.98 - 11.03	11.02 - 9.52	9.51 - 8.81	8.80 - 7.87	7.86 - 7.14	7.13 - 6.50	6.49 - 4.53	<= 4.52	No	No	--	--
Screening Mammography Positive Predictive Value 2 (PPV2 - Biopsy Recommended)	ACRAD6	Registry/QCQR	Outcome	Y	9.3	27.7	19.89 - 21.61	21.62 - 25.57	25.58 - 27.77	27.78 - 29.66	29.67 - 31.59	31.60 - 36.47	36.48 - 39.57	>= 39.58	No	No	--	--
Screening Mammography Node Negativity Rate	ACRAD7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Screening Mammography Minimal Cancer Rate	ACRAD8	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Dose Length Product for CT Head/Brain without contrast(single phase scan)	ACRAD9	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Size Specific Dose Estimate for CT Chest without contrast(single phase scan)	ACRAD10	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Dose Length Product for CT Chest without contrast (singlephase scan)	ACRAD11	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Size Specific Dose Estimate for CT Abdomen-Pelvis withContrast (single phase scan)	ACRAD12	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Dose Length Product for CT Abdomen-pelvis with contrast(single phase scan)	ACRAD13	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Participation in a National Dose Index Registry	ACRAD14	Registry/QCQR	Process	Y	1	99.5	99.59 - 99.68	99.69 - 99.84	--	99.85 - 99.88	--	99.89 - 99.98	99.99 - 99.99	100.00	Yes	No	--	--
Report Turnaround Time: Radiography	ACRAD15	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: Ultrasound (Excluding Breast US)	ACRAD16	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: MRI	ACRAD17	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Report Turnaround Time: CT	ACRAD18	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: PET	ACRAD19	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
CT IV Contrast Extravasation Rate (Low Osmolar Contrast Media)	ACRAD20	Registry/QCQR	Outcome	Y	0.1	0	0.07 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Lung Cancer Screening Cancer Detection Rate (CDR)	ACRAD21	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Lung Cancer Screening Positive Predictive Value (PPV)	ACRAD22	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Lung Cancer Screening Abnormal Interpretation Rate	ACRAD23	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hepatitis C Virus (HCV) - Sustained Virological Response	AGA1	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation	AQI18	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
New Corneal Injury Not Diagnosed in the Postanesthesia Care Unit/Recovery Area after Anesthesia Care	AQI28	Registry/QCQR	Outcome	Y	0.2	99.9	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics)	AQI29	Registry/QCQR	Process	Y	1.3	99.8	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Composite Anesthesia Safety	AQI30	Registry/QCQR	Outcome	Y	0.8	99.7	99.70 - 99.80	99.81 - 99.87	99.88 - 99.97	99.98 - 99.99	--	--	--	100.00	Yes	No	--	--
Postanesthesia Care Unit (PACU) Re-intubation Rate	AQI31	Registry/QCQR	Intermediate Out	Y	9.5	1	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Composite Procedural Safety for Central Line Placement	AQI32	Registry/QCQR	Intermediate Out	Y	1	99.8	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Composite Patient Experience	AQI33	Registry/QCQR	Process	Y	12.7	98	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Perioperative Cardiac Arrest	AQI34	Registry/QCQR	Outcome	Y	0.2	0.1	0.10 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Perioperative Mortality Rate	AQI35	Registry/QCQR	Outcome	Y	0.2	0.1	0.08 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Assessment of Acute Postoperative Pain	AQI36	Registry/QCQR	Intermediate Out	Y	1.5	99.3	98.96 - 99.43	99.44 - 99.75	99.76 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Surgical Safety Checklist ?Applicable Safety Checks Completed Before Induction of Anesthesia	AQI37	Registry/QCQR	Process	Y	0.6	99.9	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Unplanned Transfer or Admission to Hospital	AQI40	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Coronary Artery Bypass Graft (CABG): Stroke	AQI41	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Coronary Artery Bypass Graft (CABG): Post-Operative Renal Failure	AQI42	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Post-operative stroke or death in asymptomatic patients undergoing Carotid Artery Stenting (CAS)	AQI43	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Post-operative stroke or death in asymptomatic patients undergoing Carotid Endarterectomy (CEA)	AQI44	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Rate of Endovascular aneurysm repair (EVAR) of small or moderate non-ruptured abdominal aortic aneurysms (AAA) who die while in the hospital	AQI45	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation	AQI46	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet	AQI47	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prostate Cancer: Documentation of PSA, Gleason score and clinical stage for risk stratification	AQUA1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prostate Cancer: Documentation of extent of biopsy involvement in the MD note	AQUA2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys	AQUA3	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hypogonadism: Testosterone lab ordered / reported within 6 months of starting testosterone replacement	AQUA4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Benign Prostate Hyperplasia: Do not order creatinine lab for patients	AQUA5	Registry/QCQR	Process	Y	8.6	6	10.00 - 8.79	8.78 - 4.63	4.62 - 3.14	3.13 - 1.53	1.52 - 0.01	--	--	0.00	Yes	No	--	--
Benign Prostate Hyperplasia: Do not order upper-tract imaging	AQUA6	Registry/QCQR	Process	Y	8.9	7	10.77 - 8.81	8.80 - 5.53	5.52 - 4.44	4.43 - 2.55	2.54 - 0.01	--	--	0.00	Yes	No	--	--
Benign Prostate Hyperplasia: IPSS change 6 months after diagnosis	AQUA7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hospital re-admissions / complications within 30 days of TRUS Biopsy	AQUA8	Registry/QCQR	Outcome	Y	2.4	3.3	1.41 - 1.68	1.69 - 2.07	2.08 - 2.62	2.63 - 3.56	3.57 - 3.87	3.88 - 4.34	4.35 - 5.96	>= 5.97	No	No	--	--
Prostate Cancer: Use of active surveillance / watchful waiting for low-risk prostate cancer	AQUA9	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgeon assessment for hereditary cause of breast cancer	ASBS1	Registry/QCQR	Process	Y	4.6	98.7	99.34 - 99.63	99.64 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Surgical Site Infection and Cellulitis After Breast and/or Axillary Surgery	ASBS2	Registry/QCQR	Outcome	Y	1.8	1.4	2.38 - 1.60	1.59 - 1.34	1.33 - 0.93	0.92 - 0.44	0.43 - 0.01	--	--	0.00	Yes	No	--	--
Specimen orientation for partial mastectomy or excisional breast biopsy	ASBS3	Registry/QCQR	Process	Y	0.9	99.7	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Unplanned 30 day re-operation after mastectomy	ASBS7	Registry/QCQR	Outcome	Y	1.5	99.1	97.62 - 98.52	98.53 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Management of the axilla in breast cancer patients undergoing breast conserving surgery with a positive sentinel node biopsy	ASBS10	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgeon documentation of clinical stage of breast cancer	ASBS11	Registry/QCQR	Process	Y	12.2	96.1	98.54 - 99.36	99.37 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	ASNC1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	ASNC2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients	ASNC3	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Utilization of standardized nomenclature and reporting for nuclear cardiology imaging studies	ASNC4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
SPECT and PET MPI studies signed within two business days	ASNC12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
SPECT-MPI studies meeting appropriate use criteria	ASNC13	Registry/QCQR	Efficiency	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
SPECT-MPI study quality excellent or good	ASNC15	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
SPECT-MPI studies not Equivocal	ASNC17	Registry/QCQR	Efficiency	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
SPECT-MPI studies performed without the use of thallium	ASNC20	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Train of Four Monitor Documented After Last Dose of Non-depolarizing Neuromuscular Blocker	ASPIRE2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Administration of Neostigmine before Extubation for Cases with Nondepolarizing Neuromuscular Blockade	ASPIRE3	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Administration of insulin or glucose recheck for patients with hyperglycemia	ASPIRE4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Avoiding excessively high tidal volumes during positive pressure ventilation	ASPIRE6	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Active warming for all patients at risk of intraoperative hypothermia	ASPIRE7	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Core temperature measurement for all general anesthetics	ASPIRE8	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Colloid use limited in cases with no indication	ASPIRE11	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Hemoglobin or hematocrit measurement for patients receiving discretionary intraoperative red blood cell transfusions	ASPIRE12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Transfusion goal of hematocrit less than 30	ASPIRE13	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Avoiding intraoperative hypotension	ASPIRE16	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Avoiding gaps in systolic or mean arterial pressure measurement	ASPIRE17	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Avoiding myocardial injury	ASPIRE18	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Avoiding acute kidney injury	ASPIRE19	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Avoiding medication overdose	ASPIRE22	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Use of wound surface culture technique in patients with chronic skin ulcers (overuse measure)	ASPS1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Use of wet to dry dressings in patients with chronic skin ulcers (overuse measure)	ASPS2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Use of compression system in patients with venous ulcers	ASPS3	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Offloading (pressure relief) of diabetic foot ulcer	ASPS4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Breast Reconstruction: Return to OR	ASPS5	Registry/QCQR	Intermediate Out	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Breast Reconstruction: Flap Loss	ASPS6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hand Sanitation Performed By My Provider	BIVARUS1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Medication Reconciliation Performed At My Visit	BIVARUS2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Practice Asked Me About Allergies	BIVARUS3	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Practice Explained Medications Before Giving Them	BIVARUS5	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Coordination Of Care Among Physicians and Nurses	BIVARUS7	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
I Was Told How To Arrange An Appointment For Follow-Up Care	BIVARUS9	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Overall Assessment of Safety	BIVARUS10	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
The Doctor Provided Follow-Up Care Instructions In A Way I Could Understand	BIVARUS11	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
I Was Involved In Developing My Care or Follow-Up Plan	BIVARUS12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Pain Was Treated Effectively	BIVARUS13	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Doctor Listened To Me	BIVARUS16	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Doctor Made Me Feel Comfortable About Asking Questions	BIVARUS17	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Doctor Explained My Final Diagnosis	BIVARUS19	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
I Understood What the Physician Told Me	BIVARUS20	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Doctor Informed Me Of My Treatment Options	BIVARUS22	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Doctor Told Me How Long Things Would Take	BIVARUS23	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
My Doctor Did Not Seem Rushed While With Me	BIVARUS24	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
While In My Room, My Doctor Was Focused On Me/My Issues	BIVARUS25	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
How Likely Are You to Recommend This Physician to Your Family and Friends	BIVARUS26	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adequate Off-loading of Diabetic Foot Ulcers at each visit	CDR1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Diabetic Foot Ulcer (DFU) Healing or Closure	CDR2	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Diabetic Foot & Ankle Care: Comprehensive Diabetic Foot Examination	CDR4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adequate Compression at each visit for Patients with Venous Leg Ulcers (VLU)	CDR5	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Venous Leg Ulcer outcome measure: Healing or Closure	CDR6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Appropriate use of Cellular or Tissue Based Products (CTP) for patients aged 18 years or older with a diabetic foot ulcer (DFU) or venous leg ulcer (VLU)	CDR9	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Vascular Assessment of patients with chronic leg ulcers	CDR10	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Wound Bed Preparation Through Debridement of Necrotic or Non-viable Tissue	CDR11	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Wound Related Quality of Life	CDR12	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Door to Diagnostic Evaluation by a Provider ?All Emergency Department (ED) Patients	ECPR1	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Door to Diagnostic Evaluation by a Provider ?Adult Emergency Department (ED) Patients	ECPR2	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Door to Diagnostic Evaluation by a Provider ?Pediatric Emergency Department (ED) Patients	ECPR3	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Emergency Department (ED) Arrival to ED Departure for All Discharged ED Patients	ECPR4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Lower Acuity ED Patients	ECPR5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Higher Acuity ED Patients	ECPR6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Three Day All Cause Return ED Visit Rate ?All Patients	ECPR11	Registry/QCQR	Outcome	Y	1	5	5.94 - 5.66	5.65 - 5.35	5.34 - 5.10	5.09 - 4.68	4.67 - 4.42	4.41 - 4.16	4.15 - 3.64	<= 3.63	No	No	--	--
Three Day All Cause Return ED Visit Rate ?Adults	ECPR12	Registry/QCQR	Outcome	Y	1	5.4	6.25 - 6.06	6.05 - 5.67	5.66 - 5.54	5.53 - 5.16	5.15 - 4.68	4.67 - 4.41	4.40 - 3.96	<= 3.95	No	No	--	--
Three Day All Cause Return ED Visit Rate ?Pediatrics	ECPR13	Registry/QCQR	Outcome	Y	1.4	2.3	3.30 - 3.00	2.99 - 2.68	2.67 - 2.31	2.30 - 1.80	1.79 - 1.55	1.54 - 1.05	1.04 - 0.49	<= 0.48	No	No	--	--
Initiation of the Initial Sepsis Bundle	ECPR24	Registry/QCQR	Process	Y	22.7	78.2	55.81 - 78.52	78.53 - 81.23	81.24 - 87.77	87.78 - 90.64	90.65 - 94.20	94.21 - 95.44	95.45 - 97.56	>= 97.57	No	No	--	--
Door to Diagnostic Evaluation by a Provider ?All Urgent Care Patients	ECPR29	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Door to Diagnostic Evaluation by a Provider ?Adult Urgent Care Patients	ECPR30	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Door to Diagnostic Evaluation by a Provider ?Pediatric Urgent Care Patients	ECPR31	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Urgent Care Clinic (UCC) Arrival to UCC Departure for All Discharged UCC Patients	ECPR32	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Urgent Care Clinic (UCC) Arrival to UCC Departure for Adult Discharged UCC Patients	ECPR33	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Urgent Care Clinic (UCC) Arrival to UCC Departure for Pediatric Discharged UCC Patients	ECPR34	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Emergency Department (ED) Arrival to ED Departure for All Admitted ED Patients	ECPR35	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Admitted Adult ED Patients	ECPR36	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Three Day All Cause Return ED Visit Rate with Admission on Re-Visit	ECPR38	Registry/QCQR	Outcome	Y	0.4	1.5	1.92 - 1.79	1.78 - 1.62	1.61 - 1.49	1.48 - 1.34	1.33 - 1.26	1.25 - 1.18	1.17 - 0.95	<= 0.94	No	No	--	--
Avoid Head CT for Patients with Uncomplicated Syncope	ECPR39	Registry/QCQR	Process	Y	13	77.9	65.22 - 73.99	74.00 - 77.49	77.50 - 80.64	80.65 - 84.37	84.38 - 86.46	86.47 - 89.28	89.29 - 92.76	>= 92.77	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Pain Management for Long Bone Fracture	ECPR40	Registry/QCDR	Process	Y	4.9	94.6	91.67 - 92.97	92.98 - 93.74	93.75 - 95.44	95.45 - 96.42	96.43 - 97.95	97.96 - 99.99	--	100.00	Yes	No	--	--
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding	ECPR41	Registry/QCDR	Process	Y	19.2	77.8	55.22 - 67.88	67.89 - 74.73	74.74 - 84.81	84.82 - 86.89	86.90 - 90.57	90.58 - 98.27	98.28 - 99.04	>= 99.05	No	No	--	--
Overall Anesthesia Safety	EPREOP1	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Overall Mortality	EPREOP2	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
PACU Intubation Rate	EPREOP3	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Short-term Pain Management/Maximum Pain Score	EPREOP4	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Procedural Safety for Central Venous or Arterial Catheterization	EPREOP5	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgical Safety Checklist/Timeout	EPREOP6	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Corneal Injury	EPREOP7	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Failed Airway	EPREOP8	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prophylactic Antibiotic Administration	EPREOP9	Registry/QCDR	Process	Y	1.1	99.6	99.51 - 99.75	99.76 - 99.87	99.88 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Intraoperative Fire	EPREOP10	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Case Delay	EPREOP11	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Anaphylaxis	EPREOP12	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Malignant Hyperthermia	EPREOP13	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Dental Injury	EPREOP14	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned admission to ICU	EPREOP15	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned admission to Hospital	EPREOP16	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
PONV Pediatric	EPREOP17	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Procedural Site Infection	EPREOP18	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documentation of Current Medications in the Medical Record	EPREOP19	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pain Assessment and Follow-Up	EPREOP20	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Tobacco Use: Screening and Cessation Intervention	EPREOP21	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Preoperative Fluid Intake for Elective Intra-Abdominal Procedures	EPREOP22	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Readmission Within 30 Days of Principal Procedure	EPREOP23	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Overall Cardiac Arrest	EPREOP24	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient Experience	EPREOP25	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adequacy of bowel preparation	GIQIC2	Registry/QCDR	Process	Y	4.7	95.9	93.74 - 95.55	95.56 - 96.79	96.80 - 97.55	97.56 - 98.12	98.13 - 98.64	98.65 - 99.02	99.03 - 99.37	>= 99.38	Yes	No	--	--
Photodocumentation of the cecum (also known as cecal intubation rate) ?All Colonoscopies	GIQIC3	Registry/QCDR	Process	Y	2.8	97.8	96.79 - 97.61	97.62 - 98.12	98.13 - 98.47	98.48 - 98.82	98.83 - 99.08	99.09 - 99.37	99.38 - 99.68	>= 99.69	Yes	No	--	--
Photodocumentation of the cecum (also known as cecal intubation rate) ?Screening Colonoscopies	GIQIC4	Registry/QCDR	Process	Y	2.7	98.4	97.62 - 98.27	98.28 - 98.72	98.73 - 99.04	99.05 - 99.36	99.37 - 99.60	99.61 - 99.77	99.78 - 99.99	100.00	Yes	No	--	--
Incidence of perforation	GIQIC5	Registry/QCDR	Outcome	Y	0	0	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Appropriate follow-up interval for normal colonoscopy in average risk patients	GIQIC6	Registry/QCDR	Process	Y	12.1	89.4	84.56 - 88.63	88.64 - 90.71	90.72 - 92.97	92.98 - 94.38	94.39 - 95.70	95.71 - 97.21	97.22 - 98.73	>= 98.74	No	No	--	--
Age appropriate screening colonoscopy	GIQIC8	Registry/QCDR	Outcome	Y	0.3	0.1	--	--	--	--	--	--	--	0.00	Yes	No	--	--
Documentation of history and physical rate - Colonoscopy	GIQIC9	Registry/QCDR	Process	Y	4.2	99	99.37 - 99.73	99.74 - 99.89	99.90 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Appropriate management of anticoagulation in the peri-procedural period rate ?EGD	GIQIC10	Registry/QCDR	Process	Y	15.7	88.6	74.07 - 83.50	83.51 - 89.65	89.66 - 96.61	96.62 - 97.84	97.85 - 99.99	--	--	100.00	Yes	No	--	--
Helicobacter pylori (H. pylori) status rate	GIQIC11	Registry/QCDR	Process	Y	10.8	91.4	82.51 - 85.95	85.96 - 91.37	91.38 - 96.29	96.30 - 99.99	--	--	--	100.00	Yes	No	--	--
Appropriate indication for colonoscopy	GIQIC12	Registry/QCDR	Process	Y	8.1	90.3	84.85 - 87.69	87.70 - 90.11	90.12 - 92.09	92.10 - 93.79	93.80 - 95.58	95.59 - 96.90	96.91 - 98.74	>= 98.75	No	No	--	--
Repeat screening colonoscopy recommended within one year due to inadequate bowel preparation	GIQIC14	Registry/QCDR	Outcome	Y	31.8	45.8	17.65 - 24.99	25.00 - 27.41	27.42 - 31.57	31.58 - 37.28	37.29 - 69.99	70.00 - 86.95	86.96 - 93.32	>= 93.33	No	No	--	--
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients	GIQIC15	Registry/QCDR	Process	Y	16.4	80	68.00 - 75.99	76.00 - 82.34	82.35 - 85.03	85.04 - 87.87	87.88 - 90.62	90.63 - 92.30	92.31 - 95.34	>= 95.35	No	No	--	--
Adenoma detection rate	GIQIC16	Registry/QCDR	Intermediate Out	Y	11.7	40.7	30.69 - 34.35	34.36 - 36.99	37.00 - 39.87	39.88 - 43.05	43.06 - 45.82	45.83 - 49.99	50.00 - 55.65	>= 55.66	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
30 Day All Cause Re-Admission Rate for All Discharged Inpatients	HCPR6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
30 Day All Cause Re-Admission Rate Following Pneumonia Hospitalization	HCPR7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
30 Day All Cause Re-Admission Rate Following CHF Hospitalization	HCPR8	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
30 Day All Cause Re-Admission Rate Following COPD Hospitalization	HCPR9	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pain Brought Under Control within 2 Encounters	ICLOP543	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patients Treated With an Opioid Who Are Given a Bowel Regimen	ICLOP544	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Palliative Care: Pain Screening	ICLOP548	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Percentage of Palliative Care Patients With Documentation in the Clinical Record of a Discussion of Spiritual/Religious Concerns Or Documentation that the Patient/Caregiver Did Not Want to Discuss	ICLOP553	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Corneal Graft Surgery - Postoperative Improvement in Visual Acuity of 20/40 or greater	IRIS1	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Glaucoma - Intraocular Pressure (IOP) Reduction	IRIS2	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Glaucoma - Visual Field Progression	IRIS3	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Glaucoma - Intraocular Pressure Reduction Following Laser Trabeculoplasty	IRIS4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgery for Acquired Involitional Ptosis - Patients with an Improvement of Marginal Reflex Distance	IRIS5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Acquired Involitional Entropion - Normalized Lid Position After Surgical Repair	IRIS6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Amblyopia - Interocular Visual Acuity	IRIS7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgical Esotropia: Postoperative Alignment	IRIS8	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Diabetic Retinopathy - Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy	IRIS9	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Exudative Age-Related Macular Degeneration - Loss of Visual Acuity	IRIS10	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Nonexudative Age-Related Macular Degeneration - Loss of Visual Acuity	IRIS11	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Age-Related Macular Degeneration: Disease Progression	IRIS12	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Diabetic Macular Edema: Loss of Visual Acuity	IRIS13	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Acute Anterior Uveitis: Post-treatment visual acuity	IRIS16	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells	IRIS17	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Chronic Anterior Uveitis: Post-treatment visual acuity	IRIS18	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells	IRIS19	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Idiopathic Intracranial Hypertension: No worsening or improvement of mean deviation	IRIS20	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Ocular Myasthenia Gravis: Improvement of ocular deviation or absence of diplopia or functional improvement	IRIS21	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Giant Cell Arteritis: Absence of fellow eye involvement after corticosteroid treatment	IRIS22	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Procedures with statin and antiplatelet agents prescribed at discharge	M251	Registry/QCQR	Process	Y	13.7	75.4	66.13 - 67.64	67.65 - 69.04	69.05 - 75.12	75.13 - 78.78	78.79 - 83.32	83.33 - 87.65	87.66 - 93.74	>= 93.75	No	No	--	--
Amputation-free survival assessed at least 9 months following Infra Inguinal Bypass for intermittent claudication	M252	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Infringuinal bypass for claudication patency assessed at least 9 months following surgery	M253	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Amputation-free survival assessed at least 9 months following Supra-Inguinal Bypass for claudication	M254	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Amputation-free survival assessed at least 9 months following Peripheral Vascular Intervention for intermittent claudication	M255	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Peripheral Vascular Intervention patency assessed at least 9 months following infringuinal PVI for claudication	M256	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Ipsilateral stroke-free survival assessed at least 9 months following Carotid Artery Stenting for asymptomatic procedures	M257	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Ipsilateral stroke-free survival assessed at least 9 months following isolated CEA for asymptomatic procedures	M258	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Imaging-based maximum aortic diameter assessed at least 9 months following Thoracic and Complex EVAR procedures	M259	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Survival at least 9 months after elective repair of small thoracic aortic aneurysms	M2510	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Imaging-based maximum aortic diameter assessed at least 9 months following Endovascular AAA Repair procedures	M2511	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Survival at least 9 months after elective repair of small abdominal aortic aneurysms	M2512	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Survival at least 9 months after elective open repair of small abdominal aortic aneurysms	M2513	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Disease specific patient-reported outcome surveys for Varicose Vein procedures	M2514	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Medical Complications	MBS1	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgical Site Complications	MBS2	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Serious Complications	MBS3	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
MBSC Venous Thromboembolism prophylaxis adherence rates for Perioperative Care	MBS4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
MBSC Venous Thromboembolism prophylaxis adherence rates for Postoperative Care	MBS5	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
MBSC Venous Thromboembolism prophylaxis adherence rates for Post-discharge Care	MBS6	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Extended Length of Stay (LOS)	MBS7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Emergency Room (ER) visits	MBS8	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Hospital Readmission within 30 Days of Principal Procedure	MBS9	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Risk standardized rate of patients who experienced a postoperative complication within 30 days following a primary Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) or Laparoscopic Sleeve Gastrectomy (LSG) operation.	MBSAQIP1	Registry/QCQR	Outcome	Y	2.9	4.8	7.03 - 5.54	5.53 - 4.53	4.52 - 4.02	4.01 - 3.58	3.57 - 3.34	3.33 - 2.09	2.08 - 1.80	<= 1.79	Yes	No	--	--
Risk standardized rate of patients who experienced an unplanned readmission within 30 days following primary LRYGB or LSG operation. Risk standardized rate of patients who experienced a reoperation within 30 days following primary a LRYGB or LSG operation.	MBSAQIP2	Registry/QCQR	Outcome	Y	2.1	3	4.17 - 3.86	3.85 - 3.34	3.33 - 2.35	2.34 - 2.11	2.10 - 1.93	1.92 - 1.19	1.18 - 0.01	0.00	No	No	--	--
Risk standardized rate of patients who experienced a reoperation within 30 days following a primary LRYGB or LSG operation.	MBSAQIP3	Registry/QCQR	Outcome	Y	0.7	0.5	1.18 - 0.71	0.70 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Risk standardized rate of patients who experienced an anastomotic/staple line leak within 30 days following primary LRYGB or LSG operation.	MBSAQIP4	Registry/QCQR	Outcome	Y	0.6	0.2	0.31 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Risk standardized rate of patients who experienced a bleeding/hemorrhage event requiring transfusion, intervention/operation, or readmission within 30 days following primary LRYGB or LGS operation	MBSAQIP5	Registry/QCQR	Outcome	Y	0.8	0.5	1.19 - 0.57	0.56 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Risk standardized rate of patients who experienced a postoperative surgical site infection (SSI) (superficial incisional, deep incisional, or organ/space SSI) within 30 days following primary LRYGB or LSG operation	MBSAQIP6	Registry/QCQR	Outcome	Y	1	0.5	1.19 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion within 30 days following primary LRYGB or LSG operation.	MBSAQIP7	Registry/QCQR	Outcome	Y	1.4	1.3	2.04 - 1.86	1.85 - 1.85	1.84 - 1.49	1.48 - 0.01	--	--	--	0.00	Yes	No	--	--
Risk standardized rate of patients who experienced extended length of stay (> 7 days) following primary LRYGB or LSG operation	MBSAQIP8	Registry/QCQR	Outcome	Y	0.9	0.3	0.31 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Percentage of patients who had complete 30 day follow-up following any metabolic and bariatric procedure.	MBSAQIP9	Registry/QCQR	Process	Y	3.3	97.7	95.45 - 97.72	97.73 - 98.52	98.53 - 98.80	98.81 - 99.66	99.67 - 99.99	--	--	100.00	Yes	No	--	--
Perioperative Cardiac Arrest Rate	MIRAMED1	Registry/QCQR	Outcome	Y	0	100	--	--	--	--	--	--	--	100.00	Yes	No	--	--
PACU Intubation Rate	MIRAMED2	Registry/QCQR	Outcome	Y	0.5	99.8	99.80 - 99.89	99.90 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Dental Injury	MIRAMED3	Registry/QCQR	Outcome	Y	0.5	99.8	99.75 - 99.99	--	--	--	--	--	--	100.00	Yes	No	--	--
Perioperative Mortality Rate	MIRAMED4	Registry/QCQR	Outcome	Y	0	100	--	--	--	--	--	--	--	100.00	Yes	No	--	--
Adult PACU Pain Management	MIRAMED5	Registry/QCQR	Outcome	Y	0.8	99.6	99.40 - 99.59	99.60 - 99.79	99.80 - 99.89	99.90 - 99.99	--	--	--	100.00	Yes	No	--	--
Anaphylaxis During Anesthesia Care	MIRAMED6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Corneal Abrasion	MIRAMED7	Registry/QCQR	Outcome	Y	0.4	0.2	0.40 - 0.21	0.20 - 0.11	0.10 - 0.01	--	--	--	--	0.00	Yes	No	--	--
Case Cancellation Rate	MIRAMED8	Registry/QCQR	Process	Y	0.5	99.7	99.70 - 99.79	99.80 - 99.89	99.90 - 99.99	--	--	--	--	100.00	Yes	No	--	--
Case Delay Rate	MIRAMED9	Registry/QCQR	Process	Y	2.7	97.8	99.80 - 99.71	99.70 - 99.41	99.40 - 98.51	98.50 - 98.41	98.40 - 97.11	97.10 - 96.21	96.20 - 94.31	<= 94.30	No	No	--	--
Unplanned Use of Difficult Airway Equipment and/or Failed Airway	MIRAMED10	Registry/QCQR	Process	Y	0.8	99.5	99.10 - 99.49	99.50 - 99.69	99.70 - 99.89	99.90 - 99.99	--	--	--	100.00	Yes	No	--	--
Appropriate Use of Advanced Imaging by Ordering Provider	MOA2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adherence to Controlled Substance Agreement/Opiate Agreement with Corrective Actions for Violations	MOA7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Efficacy of Manipulative Medicine with Treatment Adjustment	MOA12	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Report Turnaround Time: Radiography	MSN3	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: Ultrasound (Excluding Breast US)	MSN4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: MRI	MSN5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: CT	MSN6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Report Turnaround Time: PET	MSN7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy	MUSIC1	Registry/QCQR	Process	Y	2.6	98.9	98.57 - 98.95	98.96 - 99.99	--	--	--	--	--	100.00	Yes	No	--	--
Unplanned Hospital Admission within 30 Days of TRUS Biopsy:	MUSIC2	Registry/QCQR	Outcome	Y	0.8	0.4	0.72 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients:	MUSIC3	Registry/QCQR	Process	Y	9.5	55.7	47.51 - 50.40	50.41 - 52.25	52.26 - 55.92	55.93 - 56.83	56.84 - 60.46	60.47 - 62.28	62.29 - 68.41	>= 68.42	No	No	--	--
Prostate Cancer: Proportion of patients with low-risk prostate cancer receiving active surveillance	MUSIC4	Registry/QCQR	Outcome	Y	10.2	18	9.52 - 11.85	11.86 - 13.72	13.73 - 15.89	15.90 - 17.85	17.86 - 21.56	21.57 - 27.37	27.38 - 33.32	>= 33.33	No	No	--	--
Prostate Cancer: Percentage of prostate cancer cases with a length of stay > 2 days	MUSIC5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy:	MUSIC6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prostate Biopsy: Proportion of patients undergoing initial prostate biopsy in the registry found to have prostate cancer	MUSIC7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prostate Biopsy: Proportion of patients undergoing a prostate biopsy with a PSA < 4	MUSIC8	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prostate Biopsy: Proportion of patients undergoing a repeat prostate biopsy within 12 months of their initial biopsy in the registry as a result of a finding of atypical small acinar proliferation (ASAP) as per the NCCN guidelines	MUSIC9	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Adequacy of Bowel Preparation	NHCR1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Successful Cecal Intubation	NHCR2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Incidence of perforation	NHCR3	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Repeat colonoscopy recommended due to poor bowel preparation	NHCR4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Repeat colonoscopy recommended due to piecemeal resection	NHCR5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Age inappropriate screening colonoscopy	NHCR6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documentation of family history	NHCR7	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Documentation of Indication for exam	NHCR8	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient Experience: Did the Patient Receive Adequate Instructions	NHQI24	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Perioperative Cardiac Arrest	NHQI27	Registry/QCQR	Outcome	Y	0	0	0.04 - 0.03	--	0.02 - 0.02	--	--	0.01 - 0.01	--	0.00	No	No	--	--
Perioperative Mortality Rate	NHQI28	Registry/QCQR	Outcome	Y	0	0	0.03 - 0.03	--	0.02 - 0.02	--	0.01 - 0.01	--	--	0.00	Yes	No	--	--
Critical Result: Pulmonary Embolism	NJIISMD1	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result: ICH	NJIISMD2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result: Aortic Dissection	NJIISMD3	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical test: OR Foreign Body	NJIISMD4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical test: Stroke	NJIISMD5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical test: Intracranial Hemorrhage	NJIISMD6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical test: Aortic Dissection	NJIISMD7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result: Occlusive intracranial stroke	NJIISMD8	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result: Placental abruption	NJIISMD9	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result: Ruptured ectopic pregnancy	NJIISMD10	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Critical Result: New DVT	NJISMD11	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result: Eptopic Pregnancy	NJISMD12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Test Protocol	NJISMD13	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Critical Result Protocol	NJISMD14	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Functional Outcome Assessment for Spine Intervention	NPA3	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Quality-of-Life Assessment for Spine Intervention	NPA4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient Satisfaction with Spine Care	NPA5	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Spine-related procedure site infection	NPA6	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Complication Following Spine-Related Procedure	NPA7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Hospital Mortality following Spine Procedure	NPA8	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Reoperation Following Spine Procedure Within the 30 Day Post-Operative Period	NPA10	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Readmission Following Spine Procedure Within the 30 Day Post-Operative Period	NPA11	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Participation in a Systematic National Database for Spine Care Interventions	NPA21	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Back Pain: Mental Health Assessment	OBERD1	Registry/QCQR	Process	Y	13.1	71.4	67.27 - 69.67	69.68 - 70.84	70.85 - 74.03	74.04 - 75.42	75.43 - 77.77	77.78 - 79.21	79.22 - 80.99	>= 81.00	No	No	--	--
Back Pain: Patient Reassessment	OBERD2	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Pain Assessment and Follow-Up	OBERD4	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Back Pain: Surgical Timing	OBERD5	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Orthopedic Pain: Mental Health Assessment	OBERD6	Registry/QCQR	Process	Y	14.1	81.5	70.64 - 76.44	76.45 - 80.98	80.99 - 83.57	83.58 - 87.49	87.50 - 90.57	90.58 - 95.13	95.14 - 96.67	>= 96.68	No	No	--	--
Orthopedic Pain: Patient Reassessment	OBERD7	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Orthopedic Pain: Assessment and follow-up	OBERD9	Registry/QCQR	Process	Y	11.1	67.8	58.65 - 66.18	66.19 - 69.65	69.66 - 70.74	70.75 - 72.14	72.15 - 74.18	74.19 - 75.49	75.50 - 77.03	>= 77.04	No	No	--	--
Quality of Life (VR-12 or Promis Global 10) Monitoring	OBERD10	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Quality of Life (VR-12 or Promis Global 10) Outcomes	OBERD11	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
CG-CAHPS Adult Visit Composite Tracking	OBERD12	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Orthopedic Functional and Pain Level Outcomes	OBERD13	Registry/QCQR	Outcome	Y	27.8	62.4	86.11 - 79.89	79.88 - 74.60	74.59 - 70.13	70.12 - 61.40	61.39 - 49.51	49.50 - 39.93	39.92 - 18.43	<= 18.42	No	No	--	--
Orthopedic 3-Month Surgery Follow-up	OBERD14	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Orthopedic 3-Month Surgery Outcome	OBERD15	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
CG-CAHPS Patient Rating	OBERD17	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Orthopedic Surgery 3-Month QoL Changes (VR-6D)	OBERD19	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
30 day Readmission for Acute Myocardial Infarction	PINC1	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
30 day Readmission for Heart Failure	PINC2	Registry/QCQR	Outcome	Y	6.1	14.6	18.18 - 16.68	16.67 - 16.23	16.22 - 14.72	14.71 - 13.80	13.79 - 12.21	12.20 - 10.35	10.34 - 6.68	<= 6.67	No	No	--	--
30 day Readmission for Pneumonia	PINC3	Registry/QCQR	Outcome	Y	6.9	13.8	19.23 - 15.95	15.94 - 15.01	15.00 - 12.89	12.88 - 11.12	11.11 - 9.77	9.76 - 8.34	8.33 - 5.57	<= 5.56	No	No	--	--
30 day Mortality for Acute Myocardial Infarction	PINC4	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
30 day Mortality for Heart Failure	PINC5	Registry/QCQR	Outcome	Y	3.2	2.9	4.76 - 3.61	3.60 - 3.34	3.33 - 2.57	2.56 - 1.62	1.61 - 0.01	--	--	0.00	Yes	No	--	--
30 day Mortality for Pneumonia	PINC6	Registry/QCQR	Outcome	Y	7.1	9.7	13.04 - 11.12	11.11 - 9.63	9.62 - 8.78	8.77 - 7.51	7.50 - 5.17	5.16 - 4.56	4.55 - 3.34	<= 3.33	Yes	No	--	--
Venous Thromboembolism (VTE) Prophylaxis	PINC7	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Thrombolytic Therapy	PINC21	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Discharged on Statin Medication	PINC22	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Stroke Education	PINC23	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
VTE Warfarin Therapy Discharge Instructions	PINC27	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Tobacco Use Treatment Provided or Offered	PINC28	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Time from ED Arrival to ED Departure for Admitted ED Patients	PINC29	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Admit Decision Time to ED Departure Time for Admitted Patients	PINC30	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Median Time from ED Arrival to ED Departure for Discharged ED Patients	PINC31	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Door to Diagnostic Evaluation by a Qualified Medical Professional	PINC32	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Acute Myocardial Infarction (AMI)	PINC33	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Heart Failure (HF)	PINC34	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Pneumonia (PN)	PINC35	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy (Pediatrics)	PINC44	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Post Anesthesia Care Unit (PACU) Re-intubation Rate	PINC45	Registry/QCDR	Intermediate Out	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Immediate Perioperative Cardiac Arrest	PINC46	Registry/QCDR	Intermediate Out	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Immediate Perioperative Mortality Rate	PINC47	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Composite Anesthesia Safety	PINC48	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Short-term Pain Management	PINC49	Registry/QCDR	Intermediate Out	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	PPRNET1	Registry/QCDR	Outcome	Y	11.8	68.2	62.86 - 65.41	65.42 - 68.17	68.18 - 70.02	70.03 - 72.21	72.22 - 73.54	73.55 - 76.06	76.07 - 77.13	>= 77.14	Yes	No	--	--
Diabetes Mellitus (DM): Nephropathy Assessment	PPRNET2	Registry/QCDR	Process	Y	12.6	83.1	70.12 - 78.30	78.31 - 82.11	82.12 - 88.45	88.46 - 91.58	91.59 - 91.90	91.91 - 93.32	93.33 - 95.44	>= 95.45	No	No	--	--
Hypertension (HTN): Appropriate Diagnosis	PPRNET4	Registry/QCDR	Process	Y	7.3	87.9	83.45 - 84.24	84.25 - 85.86	85.87 - 87.49	87.50 - 91.41	91.42 - 92.16	92.17 - 94.29	94.30 - 97.52	>= 97.53	No	No	--	--
Hypertension (HTN): Controlling Blood Pressure	PPRNET5	Registry/QCDR	Outcome	Y	9.4	66.5	58.33 - 60.40	60.41 - 64.27	64.28 - 65.44	65.45 - 69.23	69.24 - 71.73	71.74 - 73.96	73.97 - 79.73	>= 79.74	No	No	--	--
Concordance with ACC/AHA Cholesterol Guidelines for ASCVD Risk Reduction	PPRNET6	Registry/QCDR	Process	Y	11.2	34.4	24.62 - 25.87	25.88 - 27.98	27.99 - 30.37	30.38 - 36.94	36.95 - 40.70	40.71 - 46.66	46.67 - 49.99	>= 50.00	No	No	--	--
Antiplatelet Medication for High Risk Patients	PPRNET8	Registry/QCDR	Process	Y	19.2	49.3	27.54 - 34.44	34.45 - 48.69	48.70 - 52.69	52.70 - 58.35	58.36 - 62.68	62.69 - 68.37	68.38 - 72.62	>= 72.63	No	No	--	--
Antithrombotic Medication for Patients with Atrial Fibrillation	PPRNET9	Registry/QCDR	Process	Y	12.2	80.5	70.41 - 72.96	72.97 - 73.76	73.77 - 81.98	81.99 - 87.87	87.88 - 89.12	89.13 - 90.31	90.32 - 94.91	>= 94.92	No	No	--	--
Heart Failure (HF): ACEI or ARB Therapy	PPRNET10	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Heart Failure (HF): Beta-Blocker Therapy	PPRNET11	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Screening for Abdominal Aortic Aneurysm	PPRNET12	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Chronic Kidney Disease (CKD): eGFR Monitoring	PPRNET13	Registry/QCDR	Process	Y	15.5	71.9	64.27 - 66.85	66.86 - 70.65	70.66 - 73.32	73.33 - 77.17	77.18 - 81.20	81.21 - 84.50	84.51 - 89.99	>= 90.00	No	No	--	--
Chronic Kidney Disease (CKD): Hemoglobin Monitoring	PPRNET14	Registry/QCDR	Process	Y	15.9	80.9	62.26 - 77.26	77.27 - 79.08	79.09 - 86.62	86.63 - 89.65	89.66 - 90.47	90.48 - 93.47	93.48 - 96.14	>= 96.15	No	No	--	--
Osteoporosis Screening for Women	PPRNET15	Registry/QCDR	Process	Y	24.9	56.9	37.14 - 44.59	44.60 - 51.03	51.04 - 56.00	56.01 - 66.38	66.39 - 79.30	79.31 - 82.71	82.72 - 84.47	>= 84.48	No	No	--	--
Cervical Cancer Screening	PPRNET16	Registry/QCDR	Process	Y	21.5	39.9	25.15 - 25.55	25.56 - 30.50	30.51 - 32.45	32.46 - 40.23	40.24 - 57.13	57.14 - 58.24	58.25 - 69.56	>= 69.57	No	No	--	--
Breast Cancer Screening	PPRNET17	Registry/QCDR	Process	Y	31.9	49.2	5.37 - 15.20	15.21 - 52.75	52.76 - 64.43	64.44 - 69.99	70.00 - 74.13	74.14 - 76.66	76.67 - 77.04	>= 77.05	No	No	--	--
Colorectal Cancer screening	PPRNET18	Registry/QCDR	Process	Y	17.4	60.9	46.82 - 51.65	51.66 - 56.97	56.98 - 62.00	62.01 - 67.09	67.10 - 70.59	70.60 - 77.08	77.09 - 80.94	>= 80.95	No	No	--	--
Pneumococcal Vaccination in Elderly	PPRNET19	Registry/QCDR	Process	Y	17.9	78.5	66.89 - 73.85	73.86 - 81.52	81.53 - 83.36	83.37 - 86.34	86.35 - 88.92	88.93 - 90.80	90.81 - 93.94	>= 93.95	No	No	--	--
Zoster (Shingles) Vaccination	PPRNET20	Registry/QCDR	Process	Y	24.1	52.8	26.33 - 38.46	38.47 - 52.22	52.23 - 55.90	55.91 - 59.67	59.68 - 71.08	71.09 - 74.94	74.95 - 81.66	>= 81.67	No	No	--	--
Depression Screening	PPRNET21	Registry/QCDR	Process	Y	37	48.5	7.69 - 10.91	10.92 - 23.94	23.95 - 45.53	45.54 - 79.11	79.12 - 84.87	84.88 - 88.41	88.42 - 91.39	>= 91.40	No	No	--	--
Alcohol Misuse Screening	PPRNET22	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Tobacco Use: Screening and Cessation Intervention	PPRNET23	Registry/QCDR	Process	Y	17.9	86.2	82.06 - 86.04	86.05 - 89.46	89.47 - 92.17	92.18 - 93.87	93.88 - 95.07	95.08 - 97.21	97.22 - 99.31	>= 99.32	No	No	--	--
Appropriate Treatment for Adults with Upper Respiratory Infection	PPRNET24	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Appropriate Antibiotic Use	PPRNET25	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Use of High-Risk Medications in the Elderly	PPRNET26	Registry/QCDR	Process	Y	5	85.7	81.64 - 82.97	82.98 - 84.78	84.79 - 85.36	85.37 - 86.29	86.30 - 88.07	88.08 - 90.08	90.09 - 93.42	>= 93.43	No	No	--	--
Use of Benzodiazepines in the Elderly	PPRNET27	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
NSAID or Cox 2 Inhibitor Use in Patients with Heart Failure (HF) or Chronic Kidney Disease (CKD)	PPRNET28	Registry/QCDR	Process	Y	5.2	85.6	80.89 - 83.26	83.27 - 85.20	85.21 - 85.70	85.71 - 86.44	86.45 - 87.98	87.99 - 89.31	89.32 - 94.23	>= 94.24	No	No	--	--
Monitoring Serum Potassium	PPRNET29	Registry/QCDR	Process	Y	15.7	84.2	80.47 - 81.95	81.96 - 83.76	83.77 - 87.74	87.75 - 90.46	90.47 - 92.78	92.79 - 94.58	94.59 - 97.21	>= 97.22	No	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Treatment of Hypokalemia	PPRNET30	Registry/QCDR	Outcome	Y	3.1	96.6	94.78 - 96.66	96.67 - 97.06	97.07 - 97.51	97.52 - 98.23	98.24 - 98.51	98.52 - 98.73	98.74 - 99.10	>= 99.11	Yes	No	--	--
Screening for Type 2 Diabetes	PPRNET31	Registry/QCDR	Process	Y	10.4	87.7	81.19 - 84.51	84.52 - 87.46	87.47 - 90.78	90.79 - 92.76	92.77 - 93.62	93.63 - 95.35	95.36 - 98.07	>= 98.08	No	No	--	--
Central Venous Line: ultrasound used for placement	QUANTUM31	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Procedural Safety for Central Line Placement	QUANTUM32	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Dental Damage/Loss	QUANTUM34	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Aspiration of Gastric Contents	QUANTUM37	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prevention of Post Operative Vomiting with an appropriate medical regimen guided by risk assessment in patients aged 3 to 18 years of age	QUANTUM39	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Surgical Case Cancellation	QUANTUM41	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned Hospital Admission	QUANTUM42	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Difficult Intubation due to unrecognized difficult airway	QUANTUM43	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Medication Error by Anesthesia Care Team	QUANTUM47	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Anaphylaxis	QUANTUM48	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Immediate Perioperative Cardiac Arrest	QUANTUM49	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Unplanned ICU Admission	QUANTUM51	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Change in Functional Outcome	SPINEIQ1	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Change in Pain Intensity	SPINEIQ2	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Repeated X-Ray Imaging	SPINEIQ3	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient Satisfaction Assessment	SPINEIQ4	Registry/QCDR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Prolonged Length of Stay following CABG	STS1	Registry/QCDR	Outcome	Y	4.2	5.3	7.94 - 6.34	6.33 - 5.27	5.26 - 4.40	4.39 - 3.58	3.57 - 2.74	2.73 - 2.01	2.00 - 0.94	<= 0.93	No	No	--	--
Short Length of Stay following CABG	STS2	Registry/QCDR	Outcome	Y	16.4	41.2	25.93 - 31.02	31.03 - 36.91	36.92 - 42.10	42.11 - 47.61	47.62 - 49.99	50.00 - 55.14	55.15 - 61.69	>= 61.70	No	No	--	--
Prolonged Length of Stay following CABG and Valve Surgery	STS3	Registry/QCDR	Outcome	Y	6.7	11.1	15.38 - 14.30	14.29 - 12.51	12.50 - 10.72	10.71 - 8.21	8.20 - 6.68	6.67 - 4.77	4.76 - 3.46	<= 3.45	No	No	--	--
Short Length of Stay following CABG and Valve Surgery	STS4	Registry/QCDR	Outcome	Y	14.1	22.7	8.51 - 9.99	10.00 - 18.45	18.46 - 22.60	22.61 - 25.39	25.40 - 31.81	31.82 - 36.35	36.36 - 43.99	>= 44.00	No	No	--	--
Prolonged Length of Stay following Valve Surgery	STSS	Registry/QCDR	Outcome	Y	4.7	5.5	9.52 - 7.33	7.32 - 5.57	5.56 - 4.77	4.76 - 4.01	4.00 - 2.64	2.63 - 0.01	--	0.00	No	No	--	--
Short Length of Stay following Valve Surgery	STS6	Registry/QCDR	Outcome	Y	16.1	37.7	22.73 - 28.56	28.57 - 34.77	34.78 - 38.19	38.20 - 41.85	41.86 - 45.44	45.45 - 51.60	51.61 - 61.10	>= 61.11	No	No	--	--
Patient Centered Surgical Risk Assessment and Communication using the STS Risk Calculator	STS7	Registry/QCDR	Process	Y	38.2	47.8	4.46 - 11.69	11.70 - 23.42	23.43 - 43.58	43.59 - 69.90	69.91 - 82.75	82.76 - 89.18	89.19 - 96.68	>= 96.69	No	No	--	--
Perioperative Aspiration Pneumonia rate	THPS01	Registry/QCDR	Outcome	Y	0	0	0.05 - 0.05	0.04 - 0.03	0.02 - 0.02	--	0.01 - 0.01	--	--	0.00	Yes	No	--	--
Post-dural puncture headache rate	THPS02	Registry/QCDR	Outcome	Y	0.1	0.1	0.12 - 0.07	0.06 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Perioperative Peripheral Nerve Injury rate	THPS03	Registry/QCDR	Outcome	Y	0	0	0.02 - 0.02	--	0.01 - 0.01	--	--	--	--	0.00	Yes	No	--	--
Pneumothorax rate as a complication of central line placement	THPS04	Registry/QCDR	Outcome	N	0	0	--	--	--	--	--	--	--	0.00	--	No	--	--
Ultrasound guidance for central line placement	THPS05	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Perioperative Myocardial Infarction rate in low risk patients	THPS06	Registry/QCDR	Outcome	Y	0.1	0	0.02 - 0.02	0.01 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
Perioperative Myocardial Infarction rate in high risk patients	THPS07	Registry/QCDR	Outcome	Y	0.1	0.1	0.05 - 0.03	0.02 - 0.01	--	--	--	--	--	0.00	Yes	No	--	--
New perioperative central neurologic deficit	THPS08	Registry/QCDR	Outcome	Y	0	0	0.01 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Postoperative nausea and vomiting rate ?Adults	THPS09	Registry/QCDR	Outcome	Y	0.4	0.2	0.19 - 0.12	0.11 - 0.06	0.05 - 0.05	0.04 - 0.02	0.01 - 0.01	--	--	0.00	Yes	No	--	--
Postoperative nausea and vomiting rate ?Pediatrics	THPS010	Registry/QCDR	Outcome	Y	0.1	0.1	0.19 - 0.01	--	--	--	--	--	--	0.00	Yes	No	--	--
Post-obstructive Pulmonary Edema rate following endo-tracheal intubation	THPS011	Registry/QCDR	Outcome	Y	0	0	0.03 - 0.03	0.02 - 0.02	0.01 - 0.01	--	--	--	--	0.00	Yes	No	--	--
Respiratory Arrest in PACU rate	THPS012	Registry/QCDR	Outcome	Y	0.5	0.1	0.03 - 0.02	--	0.01 - 0.01	--	--	--	--	0.00	Yes	No	--	--
Dental Injury Rate following airway management	THPS013	Registry/QCDR	Outcome	Y	0.3	0.1	0.05 - 0.05	0.04 - 0.04	--	0.03 - 0.03	--	0.02 - 0.01	--	0.00	Yes	No	--	--
Patient Experience: Post anesthesia follow up	THPS014	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Patient Vital Sign Assessment Prior to HBOT	USWR13	Registry/QCDR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--

Measure_Name	Measure_ID	Submission_Method	Measure_Type	Benchmark	Standard_Deviation	Average	Decile_3	Decile_4	Decile_5	Decile_6	Decile_7	Decile_8	Decile_9	Decile_10	TOPPED_OUT	SevenPointCap_PY18	Topped_Out_PY2017	Topped_Out_PY2018
Blood glucose check prior to hyperbaric oxygen therapy (HBOT) treatment	USWR14	Registry/QCQR	Process	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Healing or Closure of Wagner Grade 3, 4 or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT	USWR15	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--
Complications or Side Effects among patients undergoing Treatment with HBOT	USWR18	Registry/QCQR	Outcome	N	--	--	--	--	--	--	--	--	--	--	--	No	--	--